<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0111222863
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Fermata
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DEFERASIROX
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Dispersible tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1713.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jordan Sweden Medical and Sterilization Co." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jordan Sweden Medical and Sterilization Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 513]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI ARABIAN DRUG STORE COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jordan Sweden Medical and Sterilization Co.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        V03AC03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Fermata</strong> contains an active substance called deferasirox. It is an iron chelator which is a medicine used to remove the excess iron from the body (also called iron overload). It traps and removes excess iron which is then excreted mainly in the stools.</p><p><strong>What FERMATA is used for</strong></p><p>Repeated blood transfusions may be necessary in patients with various types of anaemia (for example thalassaemia, sickle cell disease or myelodysplastic syndromes (MDS)). However, repeated blood transfusions can cause a build-up of excess iron. This is because blood contains iron and your body does not have a natural way to remove the excess iron you get with your blood transfusions. In patients with non-transfusion-dependent thalassaemia syndromes, iron overload may also develop over time, mainly due to increased absorption of dietary iron in response to low blood cell counts. Over time, the excess iron can damage important organs such as the liver and heart. Medicines called iron chelators are used to remove the excess iron and reduce the risk of it causing organ damage.</p><p><strong>Fermata</strong> is used to treat chronic iron overload caused by frequent blood transfusions in patients with beta thalassaemia major aged 6 years and older.</p><p><strong>Fermata</strong> is also used to treat chronic iron overload when deferoxamine therapy is contraindicated or inadequate in patients with beta thalassaemia major with iron overload caused by infrequent blood transfusions, in patients with other types of anaemias, and in children aged 2 to 5 years.</p><p><strong>Fermata</strong> is also used when deferoxamine therapy is contraindicated or inadequate to treat patients aged 10 years or older who have iron overload associated with their thalassaemia syndromes, but who are not transfusion dependent.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>A. Do not take Fermata:</strong></p><p>&middot;&nbsp; If you are allergic to deferasirox or any of the other ingredients of this medicine (listed in section 6). If this applies to you, tell your doctor before taking <strong>Fermata</strong>. If you think you may be allergic, ask your doctor for advice.</p><p>&middot;&nbsp; If you have moderate or severe kidney disease.</p><p>&middot;&nbsp; If you are currently taking any other iron chelator medicines.</p><p><strong>&nbsp;</strong></p><p><strong>Fermata is not recommended </strong></p><p>&middot;&nbsp; If you are at an advanced stage of myelodysplastic syndrome (MDS; decreased production of blood cells by the bone marrow) or have advanced cancer.</p><p>&nbsp;</p><p><strong>B. Take special care with Fermata</strong></p><p>Talk to your doctor or pharmacist before taking <strong>Fermata</strong>:</p><p>&middot;&nbsp; If you have a kidney or liver problem.</p><p>&middot;&nbsp; If you have a cardiac problem due to iron overload.</p><p>&middot;&nbsp; If you notice a marked decrease in your urine output (sign of kidney problem).</p><p>&middot;&nbsp; If you develop a severe rash, or difficulty breathing and dizziness or swelling mainly of the face and throat (signs of severe allergic reaction, see also section 4 &ldquo;Possible side effects&rdquo;).</p><p>&middot;&nbsp; If you experience a combination of any of the following symptoms: rash, red skin, blistering of the lips, eyes, or mouth, skin peeling, high fever, flu-like symptoms, enlarged lymph nodes (signs of severe skin reaction, see also section 4 &ldquo;Possible side effects&rdquo;).</p><p>&middot;&nbsp; If you experience a combination of drowsiness, upper right abdominal pain, yellowing or increased yellowing of your skin or eyes and dark urine (signs of liver problems).</p><p>&middot;&nbsp; If you experience difficulty thinking, remembering information, or solving problems, being less alert or aware or feeling very sleepy with low energy (signs of a high level of ammonia in your blood, which may be associated with liver or renal problems, see also section 4 &ldquo;Possible side effects&rdquo;).</p><p>&middot;&nbsp; If you vomit blood and/or have black stools.</p><p>&middot;&nbsp; If you experience frequent abdominal pain, particularly after eating or taking <strong>Fermata</strong>.</p><p>&middot;&nbsp; If you experience frequent heartburn.</p><p>&middot;&nbsp; If you have a low level of platelets or white blood cells in your blood test.</p><p>&middot;&nbsp; If you have blurred vision.</p><p>&middot;&nbsp; If you have diarrhea or vomiting.</p><p>If any of these apply to you, tell your doctor straight away.</p><p>&nbsp;</p><p><strong>Monitoring your Fermata treatment </strong></p><p>You will have regular blood and urine tests during treatment. These will monitor the amount of iron in your body (blood level of ferritin) to see how well <strong>Fermata</strong> is working. The tests will also monitor your kidney function (blood level of creatinine, presence of protein in the urine) and liver function (blood level of transaminases). Your doctor may require you to undergo a kidney biopsy, if he/she suspects significant kidney damage. You may also have MRI (magnetic resonance imaging) tests to determine the amount of iron in your liver. Your doctor will take these tests into consideration when deciding on the dose of <strong>Fermata</strong> most suitable for you and will also use these tests to decide when you should stop taking <strong>Fermata.</strong></p><p>Your eyesight and hearing will be tested each year during treatment as a precautionary measure.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;Age 65 years and over </strong></p><p><strong>Fermata</strong> can be used by people aged 65 years and over at the same dose as for other adults. Elderly patients may experience more side effects (in particular diarrhoea) than younger patients. They should be monitored closely by their doctor for side effects that may require a dose adjustment.</p><p>&nbsp;</p><p><strong>Children and adolescents </strong></p><p><strong>Fermata </strong>can be used in children and adolescents receiving regular blood transfusions aged 2 years and over and in children and adolescents not receiving regular blood transfusions aged 10 years and over. As the patient grows the doctor will adjust the dose.</p><p><strong>Fermata</strong> is not recommended for children aged under 2 years.</p><p>&nbsp;</p><p><strong>Fermata contains lactose </strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>&nbsp;</p><p><strong>C. Taking other medicines</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes in particular:</p><p>&middot;&nbsp; Other iron chelators, which must not be taken with <strong>Fermata.</strong></p><p>&middot;&nbsp; Antacids (medicines used to treat heartburn) containing aluminium, which should not be taken at the same time of day as <strong>Fermata</strong></p><p>&middot;&nbsp; Ciclosporin (used to prevent the body rejecting a transplanted organ or for other conditions, such as rheumatoid arthritis or atopic dermatitis).</p><p>&middot;&nbsp; Simvastatin (used to lower cholesterol).</p><p>&middot;&nbsp; Certain painkillers or anti-inflammatory medicines (e.g. aspirin, ibuprofen, corticosteroids).</p><p>&middot;&nbsp; Oral bisphosphonates (used to treat osteoporosis).</p><p>&middot;&nbsp; Anticoagulant medicines (used to prevent or treat blood clotting).</p><p>&middot;&nbsp; Hormonal contraceptive agents (birth control medicines).</p><p>&middot;&nbsp; Bepridil, ergotamine (used for heart problems and migraines).</p><p>&middot;&nbsp; Repaglinide (used to treat diabetes).</p><p>&middot;&nbsp; Rifampicin (used to treat tuberculosis).</p><p>&middot;&nbsp; Phenytoin, phenobarbital, carbamazepine (used to treat epilepsy).</p><p>&middot;&nbsp; Ritonavir (used in the treatment of HIV infection).</p><p>&middot;&nbsp; Paclitaxel (used in cancer treatment).</p><p>&middot;&nbsp; Theophylline (used to treat respiratory diseases such as asthma).</p><p>&middot;&nbsp; Clozapine (used to treat psychiatric disorders such as schizophrenia).</p><p>&middot;&nbsp; Tizanidine (used as a muscle relaxant).</p><p>&middot;&nbsp; Cholestyramine (used to lower cholesterol levels in the blood).</p><p>&middot;&nbsp; Busulfan (used as a treatment prior to transplantation in order to destroy the original bone marrow before the transplant).</p><p>Additional tests may be required to monitor the blood levels of some of these medicines.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>D. Pregnancy and breast-feeding </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p><strong>Fermata</strong> is not recommended during pregnancy unless clearly necessary.</p><p>If you are currently using an oral contraceptive or using a patch contraceptive to prevent pregnancy, you should use an additional or different type of contraception (e.g. condom), as <strong>Fermata</strong> may reduce the effectiveness of oral and patch contraceptives.</p><p>Breast-feeding is not recommended during treatment with <strong>Fermata</strong>.</p><p>&nbsp;</p><p><strong>E. Driving and using machines </strong></p><p>If you feel dizzy after taking <strong>Fermata</strong>, do not drive or operate any tools or machines until you are feeling normal again.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Treatment with <strong>Fermata</strong> will be overseen by a doctor who is experienced in the treatment of iron overload caused by blood transfusions.</p><p>Always take this medicine exactly as your doctor has told you. It is important to check with your doctor or pharmacist if you are not sure.</p><p>The score line is considered as a part of the tablet description and not to drive into equal doses</p><p><strong>&nbsp;</strong></p><p>The dose of <strong>Fermata</strong> is related to body weight for all patients. Your doctor will calculate the dose you need and tell you how many tablets to take each day.</p><p>&middot;&nbsp; The usual daily dose for <strong>Fermata</strong> dispersible tablets at the start of the treatment for patients receiving regular blood transfusions is 20 mg per kilogram body weight. A higher or lower starting dose may be recommended by your doctor based on your individual treatment needs.</p><p>&middot;&nbsp; The usual daily dose for <strong>Fermata</strong> dispersible tablets at the start of the treatment for patients not receiving regular blood transfusions is 10 mg per kilogram body weight.</p><p>&middot;&nbsp; Depending on how you respond to treatment, your doctor may later adjust your treatment to a higher or lower dose.</p><p>&middot;&nbsp; The maximum recommended daily dose for <strong>Fermata</strong> dispersible tablets is 40 mg per kilogram body weight for patients receiving regular blood transfusions, 20 mg per kilogram body weight for adult patients not receiving regular blood transfusions and 10 mg per kilogram body weight for children and adolescents not receiving regular blood transfusions.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>When to take Fermata </strong></p><p>&middot;&nbsp;&nbsp; Take <strong>Fermata</strong> once a day, every day, at about the same time each day.</p><p>&middot;&nbsp;&nbsp; Take the <strong>Fermata</strong> dispersible tablets on an empty stomach.</p><p>&middot;&nbsp;&nbsp; Then wait at least 30 minutes before eating any food.</p><p>Taking <strong>Fermata</strong> at the same time each day will also help you remember when to take your tablets.</p><p><strong><u>&nbsp;</u></strong></p><p><strong>How to take Fermata</strong></p><p>&middot;&nbsp;&nbsp; Drop<strong> </strong>the tablet(s) into a glass of water, or apple or orange juice (100 to 200 ml).</p><p>&middot;&nbsp;&nbsp; Stir until the tablet(s) dissolve completely. The liquid in the glass will look cloudy.</p><p>&middot;&nbsp;&nbsp; Drink<strong> </strong>everything in the glass. Then add a little water or juice to what is left in the glass, swirl the liquid around and drink that too.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</p><p><img src="data:image/png;base64,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" alt="" width="230" height="74" vspace="0" hspace="0" border="0" style="width:230px;height:74px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>Do not dissolve the tablets in fizzy drinks or milk.</p><p>Do not chew, break or crush the tablets.</p><p>Do not swallow the tablets whole.</p><p><strong>&nbsp;</strong></p><p><strong>How long to take Fermata</strong></p><p><strong>Continue taking Fermata every day for as long as your doctor tells you. </strong>This is a long-term treatment, possibly lasting for months or years. Your doctor will regularly monitor your condition to check that the treatment is having the desired effect (see also section 2: &ldquo;Monitoring your <strong>Fermata</strong> treatment&rdquo;).</p><p>If you have questions about how long to take <strong>Fermata</strong>, talk to your doctor.</p><p>&nbsp;</p><p><strong>A.&nbsp;&nbsp;&nbsp; </strong><strong>If you take more Fermata than you should </strong></p><p>If you have taken too much <strong>Fermata</strong>, or if someone else accidentally takes your tablets, contact your doctor or hospital for advice straight away. Show them the pack of tablets. Medical treatment may be necessary.</p><p><strong>B.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>If you forget to take Fermata </strong></p><p>If you miss a dose, take it as soon as you remember on that day. Take your next dose as scheduled. Do not take a double dose on the next day to make up for the forgotten tablet(s).</p><p><strong>C.&nbsp;&nbsp;&nbsp; </strong><strong>If you stop taking Fermata </strong></p><p>Do not stop taking <strong>Fermata</strong> unless your doctor tells you to. If you stop taking it, the excess iron will no longer be removed from your body (see also above section &ldquo;How long to take <strong>Fermata</strong>&rdquo;).</p><p><strong>If you have any further questions on the use of this product, ask your doctor or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Most of the side effects are mild to moderate and will generally disappear after a few days to a few weeks of treatment.</p><p><strong>&nbsp;</strong></p><p><strong>Some side effects could be serious and need immediate medical attention. </strong></p><p><em>These side effects are uncommon (may affect up to 1 in 100 people) or rare (may affect up to 1 in 1,000 people). </em></p><p>&middot;&nbsp; If you get a severe rash, or difficulty breathing and dizziness or swelling mainly of the face and throat (signs of severe allergic reaction).</p><p>&middot;&nbsp; If you experience a combination of any of the following symptoms: rash, red skin, blistering of the lips, eyes, or mouth, skin peeling, high fever, flu-like symptoms, enlarged lymph nodes, (signs of severe skin reactions).</p><p>&middot;&nbsp; If you notice a marked decrease in your urine output (sign of kidney problem).</p><p>&middot;&nbsp; If you experience a combination of drowsiness, upper right abdominal pain, yellowing or increased yellowing of your skin or eyes and dark urine (signs of liver problems).</p><p>&middot;&nbsp; If you experience difficulty thinking, remembering information, or solving problems, being less alert or aware or feeling very sleepy with low energy (signs of a high level of ammonia in your blood, which may be associated with liver or renal problems and lead to a change in your brain function).</p><p>&middot;&nbsp; If you vomit blood and/or have black stools.</p><p>&middot;&nbsp; If you experience frequent abdominal pain, particularly after eating or taking <strong>Fermata.</strong></p><p>&middot;&nbsp; If you experience frequent heartburn.</p><p>&middot;&nbsp; If you experience partial loss of vision.</p><p>&middot;&nbsp; If you experience severe upper stomach pain (pancreatitis).</p><p><strong>&nbsp;</strong></p><p><strong>Stop taking this medicine and tell your doctor straight away</strong></p><p><strong>&nbsp;</strong></p><p><strong>Some side effects could become serious. </strong></p><p><em>These side effects are uncommon. </em></p><p>&middot;&nbsp; If you get blurred or cloudy eyesight.</p><p>&middot;&nbsp; If you get reduced hearing.</p><p><strong>Tell your doctor as soon as possible. </strong></p><p><strong>&nbsp;</strong></p><p><strong>Other side effects </strong></p><p><em>Very common (may affect more than 1 in 10 people</em>)</p><p>&middot;&nbsp; &nbsp;Disturbance in kidney function tests.</p><p><em>Common (may affect up to 1 in 10 people) </em></p><p>&middot;&nbsp;&nbsp; Gastrointestinal disorders, such as nausea, vomiting, diarrhoea, pain in the abdomen, bloating, constipation, indigestion</p><p>&middot;&nbsp;&nbsp; Rash</p><p>&middot;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp; Disturbance in liver function tests</p><p>&middot;&nbsp;&nbsp; Itching</p><p>&middot;&nbsp;&nbsp; Disturbance in urine test (protein in the urine)</p><p>If any of these affects you severely, tell your doctor.</p><p><em>Uncommon (may affect up to 1 in 100 people) </em></p><p>&middot;&nbsp;&nbsp; Dizziness</p><p>&middot;&nbsp;&nbsp; Fever</p><p>&middot;&nbsp;&nbsp; Sore throat</p><p>&middot;&nbsp;&nbsp; Swelling of arms or legs</p><p>&middot;&nbsp;&nbsp; Change in the colour of the skin</p><p>&middot;&nbsp;&nbsp; Anxiety</p><p>&middot;&nbsp;&nbsp; Sleep disorder</p><p>&middot;&nbsp;&nbsp; Tiredness</p><p>If any of these affects you severely, tell your doctor.</p><p>&nbsp;</p><p><strong>Frequency not known </strong>(cannot be estimated from the available data).</p><p>&middot;&nbsp;&nbsp; A decrease in the number of cells involved in blood clotting (thrombocytopenia), in the number of red blood cells (anaemia aggravated), in the number of white blood cells (neutropenia) or in the number of all kinds of blood cells (pancytopenia)</p><p>&middot;&nbsp;&nbsp; Hair loss</p><p>&middot;&nbsp;&nbsp; Kidney stones</p><p>&middot;&nbsp;&nbsp; Low urine output</p><p>&middot;&nbsp;&nbsp; Tear in stomach or intestine wall that can be painful and cause nausea</p><p>&middot;&nbsp;&nbsp; Severe upper stomach pain (pancreatitis)</p><p>&middot;&nbsp;&nbsp;Abnormal level of acid in blood</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Keep this medicine out of the sight and reach of children.</p><p>- Do not use <strong>Fermata </strong>after the expiry date which is stated on the blister and carton.</p><p>- This medicinal product does not require any special storage conditions, store below 30<sup>o</sup>C.</p><p>- Do not use any <strong>Fermata </strong>pack that is damaged or shows signs of tampering.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>A. What Fermata contains:</strong><strong> </strong></p><p>The active substance is deferasirox.</p><p><strong>Fermata &nbsp;250 mg</strong> contains 250 mg Deferasirox.</p><p><strong>Fermata </strong><strong><sup>&nbsp;</sup></strong><strong>500 mg</strong> contains 500 mg Deferasirox.</p><p>The other ingredients are: &nbsp;Lactose, Crospovidone, Povidone, Sodium Lauryl Sulfate, Sucralose, Sodium bicarbonate, Citric acid, Colloidal Silicone Dioxide, and Sodium Stearyl Fumerate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Fermata is supplied as Pharmaceutical Form: dispersible tablets. 
Fermata  250 mg has pack size of 30 Dispersible Tablet
Fermata 500 mg has a pack size of 30 Dispersible Tablet

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jordan Sweden Medical and Sterilization Company (JOSWE-medical)</p><p>P.O. Box 851831 Amman 11185 Jordan</p><p>E-mail: info@joswe.com</p><p>www.joswe.com</p><p>Tel: +962 6 5859765, +962 6 5728327</p><p>Fax: +962 6 5814526, +962 6 5728326</p><p>&nbsp;</p><p><strong>E.&nbsp;&nbsp;&nbsp; </strong><strong>To reports any side effect (s):</strong></p><p><strong>Contact JOSWE Medical:</strong></p><p><strong>Saudipv@josweplant.com</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance Centre (NPC):</p><p>&bull; SFDA Call Center: 19999</p><p>&bull; E-mail: npc.drug@sfda.gov.sa</p><p>&bull; Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&bull; A medicament is a product that affects your health, and its consumption contrary to instructions is</p><p>dangerous for you.</p><p>&bull; Follow strictly the doctor&#39;s prescription, the method of use and the instructions of the pharmacist</p><p>who dispensed the medicament.</p><p>&bull; The doctor and the pharmacist are experts in medicine.</p><p>&bull; Do not by yourself interrupt the period of treatment prescribed for you.</p><p>&bull; Do not repeat the same prescription without consulting your doctor.</p><p>&bull; Keep medicaments out of the reach of children.</p><p>COUNCIL OF ARAB HEALTH MINISTRIES</p><p>UNION OF ARAB PHARMACISTS</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>N666/11-08-2021/R0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 00</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 08/2021; Revision number R0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي <strong>فيرماتا</strong> على المادة الفعالة ديفيرازيروكس.&nbsp; وهو معامل مستخلب للحديد يعمل على إزالة الحديد الزائد من الجسم عن طريق الارتباط &nbsp;به الزائد ومن ثم يقوم الجسم بالتخلص من المركب الناتج عن طريق البراز بشكل أساسي.</p><p dir="RTL"><strong>استخدامات فيرماتا</strong></p><p dir="RTL">قد يكون من الضروري تكرار عمليات نقل الدم للمرضى الذين يعانون من أنواع مختلفة من فقر الدم (مثل الثلاسيميا، مرض الخلايا المنجلية أو متلازمات خلل التنسج النقوي (MDS)). يمكن أن تتسبب عمليات نقل الدم المتكررة تراكم الحديد الزائد. وذلك لأن الدم يحتوي على الحديد والجسم ليس لديه طريقة طبيعية للتخلص من الحديد الزائد الذي يحصل عليه &nbsp;من عمليات نقل الدم. المرضى الذين يعانون من متلازمات الثلاسيميا التي لا تعتمد على نقل الدم، مع مرور الوقت قد&nbsp; يصبح تركيز الحديد فائضاً، ويرجع ذلك بشكل رئيسي إلى زيادة امتصاص الحديد من الغذاء بسبب انخفاض عدد خلايا الدم. مع مرور الوقت، الحديد الزائد يمكن أن يضر أعضاء هامة مثل الكبد والقلب. الأدوية التي تسمى أدوية استخلاب الحديد تستخدم لإزالة الحديد الزائد والحد من تلف الأعضاء.</p><p dir="RTL">يستخدم <strong>فيرماتا</strong> لعلاج زيادة تركيزالحديد المزمن الناجم عن عمليات نقل الدم المتكررة للمرضى الذين يعانون من مرض بيتا الثلاسيميا و الذين تتراوح أعمارهم بين ٦ سنوات أو أكثر.</p><p dir="RTL">يستخدم <strong>فيرماتا</strong> أيضا لعلاج زيادة تركيزالحديد المزمن عندما يكون من الممنوع أو من غير الكافي استخدام ديفيروكسامين للمرضى الذين يعانون من مرض بيتا ثلاسيميا مع الحديد الزائد الناجم عن عمليات نقل الدم، و للمرضى الذين يعانون من أنواع أخرى من فقر الدم، وللأطفال الذين تتراوح أعمارهم بين ۲ إلى ٥ سنوات.</p><p dir="RTL">يستخدم <strong>فيرماتا </strong>عندما يكون من الممنوع أو من غير الكافي أيضاً استخدام ديفيروكسامين لعلاج المرضى الذين تتراوح أعمارهم بين ۱۰ سنوات أو أكثر ولديهم تراكم بالحديد المرتبط بالثلاسيميا، ولكن ليسوا معتمدين على نقل الدم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أ) لا تأخذ فيرماتا:</strong></p><p dir="RTL">&bull; إذا كان لديك حساسية من المادة الفعالة ديفيرازيروكس أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم٦)</p><p dir="RTL">إذا كان ما سبق ينطبق عليك أو إذا كنت تعتقد انك قد تعاني من الحساسية، تحدث إلى طبيبك أو إلى الصيدلاني قبل تناول <strong>فيرماتا</strong> .</p><p dir="RTL">&bull; إذا كان لديك خلل معتدل أو شديد في الكلى.</p><p dir="RTL">&bull; إذا كنت تأخذ أي أدوية أخرى من معاملات استخلاب الحديد.</p><p dir="RTL"><strong>لا ينصح باستخدام فيرماتا في الحالات التالية:&nbsp; </strong></p><p dir="RTL">&bull; إذا كنت في مرحلة متقدمة من متلازمة خلل التنسج النخاعي (MDS؛ انخفاض إنتاج خلايا الدم في نخاع العظام) أو مراحل متقدمة من السرطان.</p><p dir="RTL"><strong>&nbsp;ب) أخذ الحيطة والحذر مع فيرماتا: </strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل تناول <strong>فيرماتا</strong><strong><sup>:</sup></strong></p><p dir="RTL">&bull; إذا كنت تعاني من مشاكل في الكبد أو الكلى.</p><p dir="RTL">&bull; إذا كنت تعاني من مشاكل في القلب بسبب تراكم الحديد.</p><p dir="RTL">&bull; إذا لاحظت انخفاض في كمية إنتاج البول (علامة على وجود مشكلة في الكلى).</p><p dir="RTL">&bull; إذا اصبت بطفح جلدي شديد، صعوبة بالتنفس , دوخة أو تورم بشكل ملحوظ في الوجه والحلق (علامات تحسس &nbsp;شديدة).</p><p dir="RTL">&bull; إذا اصبت ب طفح جلدي شديد، احمرار في الجلد ، تقرحات الشفتين، والعينين، أو الفم، تقشير الجلد، وارتفاع درجة الحرارة، وأعراض تشبه الإنفلونزا، وتضخم الغدد الليمفاوية (علامات رد فعل &nbsp;حاد للجلد )</p><p dir="RTL">&bull; إذا اصبت بمزيج من الخمول، وآلام أعلى البطن الأيمن، اصفرار أو زيادة اصفرار الجلد أو العينين والبول الداكن (علامات مشاكل في الكبد).</p><p dir="RTL">&bull; إذا واجهت صعوبة في التفكير، أو تذكر المعلومات، أو حل المشاكل، أو أن تكون أقل يقظة، أو أقل وعي، أو أن تشعر بالنعاس الشديد مع انخفاض الطاقة الجسدية (علامات تدل على ارتفاع مستوى الأمونيا في الدم، والتي قد تكون مرتبطة مع مشاكل &nbsp;في الكبد أو الكلى).</p><p dir="RTL">&bull; إذا تتقيأت دم و / أو لديك براز أسود.</p><p dir="RTL">&bull; إذا واجهت ألم متكرر في البطن، و خاصة بعد تناول <strong>فيرماتا</strong>.</p><p dir="RTL">&bull; إذا واجهت حرقة متكررة.</p><p dir="RTL">&bull; إذا واجهت انخفاض في مستوى الصفائح الدموية أو خلايا الدم البيضاء في اختبار الدم.</p><p dir="RTL">&bull; إذا واجهت عدم وضوح بالرؤية.</p><p dir="RTL">&bull; إذا واجهت مشاكل الإسهال أو القيء.</p><p dir="RTL">إذا كان أي مما سبق ينطبق عليك، أخبر طبيبك فورا.</p><p dir="RTL"><strong>مراقبة العلاج فيرماتا :</strong></p><p dir="RTL">ستخضع لفحوصات الدم والبول بشكل دوري خلال فترة العلاج. وهذا يعد أساسي لمراقبة كمية الحديد في الجسم (تركيز الفيريتين في الدم) وذلك لمعرفة مدى فعالية العلاج <strong>فيرماتا</strong>. كما ستراقب هذه الفحوصات وظائف الكلى (تركيز الكرياتينين في الدم، وجود البروتين في البول) ووظائف الكبد (تركيز الترانساميناسات في الدم). قد يطلب منك طبيبك أيضاً الخضوع لخزعة من الكلى، إذا كان يشك في حدوث تلف كبير في الكلى. وقد تخضع أيضًا للتصوير بالرنين المغناطيسي لتحديد كمية الحديد في الكبد. سيعتمد طبيبك على نتائج هذه الاختبارات وقراءاتها في اتخاذ القرارالمتعلق بجرعة <strong>فيرماتا</strong> الواجب استخدامها و لتحديد متى يجب ايقاف تناول <strong>فيرماتا</strong>.</p><p dir="RTL">سيتم فحص البصر والسمع كل عام خلال فترة العلاج كإجراء وقائي.</p><p dir="RTL"><strong>كبار السن (٦٥ سنة فأكثر) </strong></p><p dir="RTL">يمكن استخدام <strong>فيرماتا</strong><strong><sup> </sup></strong>لكبار السن بنفس الجرعة التي يستخدمها البالغون الآخرون. قد يعاني المرضى كبار السن من آثار جانبية أكثر من المرضى الأصغر سناً كالإسهال. وينبغي أن يراقب عن كثب من قبل الطبيب لرصد الآثار الجانبية التي قد تتطلب تعديل الجرعة.</p><p dir="RTL"><strong>الأطفال والمراهقون </strong></p><p dir="RTL">يمكن استخدام <strong>فيرماتا</strong> للأطفال والمراهقين الذين ينقلون الدم بشكل دوري والتي تتراوح أعمارهم بين عامين وأكثر و للأطفال والمراهقين الذين لا ينقلون الدم بشكل دوري و تتراوح أعمارهم بين ۱۰أعوام فما فوق. مع نمو المريض سوف يضبط الطبيب الجرعة.</p><p dir="RTL">لا ينصح استخدام <strong>فيرماتا</strong> للأطفال الذين تقل أعمارهم عن سنتين.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>فيرماتا</strong> <strong>يحتوي على اللاكتوز: </strong></p><p dir="RTL">إذا كان طبيبك قد أخبرك بأن لديك &nbsp;مشكلة بعمليات الأيض لبعض السكريات، فاتصل بطبيبك قبل استخدام هذا الدواء.</p><p dir="RTL"><strong>ج) استخدام أدوية أخرى:</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تأخذ أو أخذت مؤخرا أو قد تأخذ أي أدوية أخرى.</p><p dir="RTL">ويشمل ذلك على وجه الخصوص:</p><p dir="RTL">&bull; معاملات استخلاب الحديد الأخرى، الواجب عدم استخدامها مع <strong>فيرماتا</strong>.</p><p dir="RTL">&bull; مضادات الحموضة التي تحتوي على الألومنيوم (الأدوية المستخدمة لعلاج حرقة المعدة) ، والتي لا ينبغي أن تؤخذ في نفس الوقت من اليوم مع <strong>فيرماتا</strong><strong><sup>.</sup></strong></p><p dir="RTL">&bull; سيكلوسبورين (وهو ما يستخدم عند زراعة الأعضاء لمنع الجسم من رفض عضو مزروع أو يستخدم لظروف أخرى مثل التهاب المفاصل الروماتويدي أو التهاب الجلد التأتبي).</p><p dir="RTL">&bull; سيمفاستاتين (يستخدم لخفض الكولسترول).</p><p dir="RTL">&bull; بعض المسكنات أو الأدوية المضادة للالتهاب (مثل الأسبرين، ايبوبروفين، الكورتيكوستيرويدات).</p><p dir="RTL">&bull; البيسفوسفونات عن طريق الفم (يستخدم لعلاج هشاشة العظام).</p><p dir="RTL">&bull; الأدوية المضادة للتخثر (يستخدم لمنع أو علاج تخثر الدم).</p><p dir="RTL">&bull; أدوية منع الحمل الهرمونية (أدوية تحديد النسل).</p><p dir="RTL">&bull; بيبرديل، إرغوتامين (يستخدم لمشاكل القلب والصداع النصفي).</p><p dir="RTL">&bull; ريباجلينيد (يستخدم لعلاج مرض السكري).</p><p dir="RTL">&bull; ريفامبيسين (يستخدم لعلاج السل).</p><p dir="RTL">&bull; الفينيتوين، فينوباربيتال، كاربامازيبين (يستخدم لعلاج الصرع).</p><p dir="RTL">&bull; ريتونافير (يستخدم في علاج عدوى فيروس نقص المناعة البشرية).</p><p dir="RTL">&bull; باكليتاكسيل (يستخدم في علاج السرطان).</p><p dir="RTL">&bull; الثيوفيلين (يستخدم لعلاج أمراض الجهاز التنفسي مثل الربو).</p><p dir="RTL">&bull; كلوزابين (يستخدم لعلاج الاضطرابات النفسية مثل الفصام).</p><p dir="RTL">&bull; تيزانيدين (يستخدم كمرخي العضلات).</p><p dir="RTL">&bull; الكولسترامين (يستخدم لخفض مستويات الكوليسترول في الدم).</p><p dir="RTL">&bull; بوسلفان (يستخدم كعلاج قبل الزرع من أجل تدمير نخاع العظم الأصلي قبل الزرع).</p><p dir="RTL">قد تكون هناك حاجة إلى فحوصات إضافية لمراقبة مستويات الدم في بعض هذه الأدوية.</p><p dir="RTL"><strong>د)الحمل والرضاعة الطبيعية </strong></p><p dir="RTL">إذا كنت حاملاً أو تقومين بالرضاعة الطبيعية، أو تعتقدين أنك حامل أو تخططين لإنجاب طفل، فاسألي طبيبك للحصول على المشورة قبل استخدام هذا الدواء. لا ينصح باستخدام <strong>فيرماتا</strong><strong><sup> </sup></strong>أثناء الحمل إلا عند الضرورة.</p><p dir="RTL">إذا كنت تستخدم وسائل منع الحمل عن طريق الفم أو لاصق, يجب عليك استخدام نوع إضافي أو مختلف من وسائل منع الحمل (مثل الواقي الذكري)، لأن <strong>فيرماتا</strong><strong><sup> </sup></strong>قد يقلل من فعالية وسائل منع الحمل عن طريق الفم &nbsp;واللاصقات.</p><p dir="RTL">لا ينصح بالرضاعة الطبيعية أثناء العلاج مع فيرماتا.</p><p dir="RTL"><strong>ه) القيادة واستخدام الآلات </strong></p><p dir="RTL">إذا كنت تشعر بالدوار بعد تناول <strong>فيرماتا</strong><strong><sup> </sup></strong>، لا تقم بقيادة السيارة أو تشغيل أي أدوات أو آلات الى أن تشعربأنك طبيعي مرة أخرى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ان العلاج <strong>بفيرماتا</strong> سيتم الإشراف عليه من قبل الطبيب المختص بعلاج تراكم الحديد الناتج عن نقل الدم.</p><p dir="RTL">&nbsp;تناول هذا الدواء تمامًا كما أخبرك طبيبك. ومن المهم أن تتحقق مع طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p dir="RTL">الخط الموجود على قرص فيرماتا هو جزء من الشكل الخارجي للقرص وليس مخصصاً لكسره لجرعتين متساويتين.</p><p dir="RTL">تعتمد جرعة <strong>فيرماتا</strong><strong><sup> </sup></strong>على وزن الجسم لجميع المرضى. سيقوم طبيبك بحساب الجرعة التي تحتاجها وإخبارك كم عدد الأقراص التي يجب تناولها كل يوم.</p><p dir="RTL">&bull; ۲۰ ملغم لكل كيلوغرام من وزن الجسم هي الجرعة اليومية المعتادة لأقراص <strong>فيرماتا</strong><strong><sup> </sup></strong>القابلة للذوبان في بداية العلاج للمرضى الذين ينلقون الدم بشكل دوري. بناءً على احتياجات العلاج الفردية قد يوصي طبيبك بدايةً بجرعة أعلى أو أقل.</p><p dir="RTL">&bull; ۱۰ ملغم لكل كيلوغرام من وزن الجسم هي الجرعة اليومية المعتادة لأقراص <strong>فيرماتا</strong><strong><sup> </sup></strong>القابلة للذوبان في بداية العلاج للمرضى الذين لا يتلقون الدم بشكل دوري.</p><p dir="RTL">&bull; اعتمادا على كيفية الاستجابة للعلاج، قد يقوم طبيبك في وقت لاحق بتعديل العلاج إلى جرعة أعلى أو أقل.</p><p dir="RTL">&bull; الحد الأقصى للجرعة اليومية الموصى بها لأقراص <strong>فيرماتا </strong>القابلة للذوبان هو ٤۰ ملغم لكل كيلوغرام من وزن الجسم للمرضى الذين يتلقون عمليات نقل الدم بشكل دوري، ۲۰ ملغم لكل كيلوغرام من وزن الجسم للمرضى البالغين الذين لا يتلقون عمليات نقل الدم بشكل دوري و ۱۰ ملغم لكل كيلوغرام من وزن الجسم للأطفال والمراهقين الذين لا يتلقون عمليات نقل الدم بشكل دوري.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>متى تستخدم فيرماتا</strong><strong><sup>:</sup></strong></p><ul><li dir="RTL">تناول <strong>فيرماتا</strong><strong><sup> </sup></strong>مرة واحدة في اليوم، في نفس الوقت من اليوم، كل يوم.</li><li dir="RTL">تناول أقراص <strong>فيرماتا</strong><strong><sup> </sup></strong>القابلة للذوبان على معدة فارغة.</li><li dir="RTL">ثم انتظر لمدة ۳۰ دقيقة على الأقل قبل تناول أي طعام.</li></ul><p dir="RTL">تناول <strong>فيرماتا</strong><strong><sup> </sup></strong>في نفس الوقت من كل يوم سوف يساعدك أيضا على تذكر موعد تناول الأقراص.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>كيفية تناول فيرماتا</strong></p><p dir="RTL">&bull; ضع قرص أو أقراص <strong>فيرماتا</strong><strong><sup> </sup></strong>في كوب من الماء، أو عصير التفاح أو البرتقال (۱۰۰ إلى ۲۰۰ مل).</p><p dir="RTL">&bull; حرّك حتى يذوب القرص تمامًا, سيبدوا السائل في الزجاج عكراً.</p><p dir="RTL">&bull; اشرب كل ما في الكوب. ثم أضف القليل من الماء أو العصير إلى ما تبقى من الكوب، حركه جيدا ثم أشرب ذلك أيضا.</p><p dir="RTL"><img src="data:image/png;base64,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" alt="" width="230" height="74" vspace="0" hspace="0" border="0" style="width:230px;height:74px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تقم بإذابة الأقراص في المشروبات الغازية أو الحليب.</p><p dir="RTL">لا تقم بمضغ، كسر أو سحق الأقراص.</p><p dir="RTL">لا تقم بابتلاع الأقراص كاملة كما هي.</p><p dir="RTL"><strong>مدة العلاج بفيرماتا</strong><strong><sup>:</sup></strong></p><p dir="RTL">استمر بتناول <strong>فيرماتا</strong><strong><sup> </sup></strong>كل يوم حسب تعليمات الطبيب. يستمر هذا العلاج لفترة طويلة من الزمن ربما أشهر أو سنوات. سيقوم طبيبك بمراقبة حالتك بانتظام للتأكد من أن العلاج يعطي النتائج المطلوبة</p><p dir="RTL">إذا كان لديك أسئلة حول مدة تناول<strong> فيرماتا</strong><strong><sup> </sup></strong>&nbsp;، فتحدث إلى طبيبك.</p><p dir="RTL">أ<strong>. إذا تناولت فيرماتا أكثر مما يجب</strong></p><p dir="RTL">إذا تناولت الكثير من <strong>فيرماتا</strong>، أو إذا تناول شخص آخر عن غير قصد<strong>، </strong>اتصل بطبيبك أو المستشفى للحصول على المشورة الطبية فورا.&nbsp; أرهم عبوة الأقراص. قد تكون هناك ضرورة لعلاج طبي.</p><p dir="RTL"><strong>ب. إذا نسيت أن تتناول فيرماتا</strong><strong><sup>:</sup></strong><strong> </strong></p><p dir="RTL">إذا نسيت أن تتناول <strong>فيرماتا </strong>قم بتناولها بمجرد تذكرك لها في نفس اليوم. تناول الجرعة التالية كما هو مقرر. لا تتناول جرعة مضاعفة في اليوم التالي للتعويض عن الجرعة المنسية.</p><p dir="RTL"><strong>ج. إذا توقفت عن تناول فيرماتا:</strong></p><p dir="RTL">لا تتوقف عن تناول <strong>فيرماتا</strong> إلا إذا أخبرك طبيبك بذلك. إذا توقفت عن تناوله، لن يتم إزالة الحديد الزائد من جسمك (انظر أيضا القسم أعلاه &quot; مدة العلاج <strong>بفيرماتا</strong>&quot;).</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، هذا الدواء قد يسبب آثار جانبية وعلى الرغم من عدم حدوثها لدى الجميع. معظم الآثار الجانبية خفيفة إلى متوسطة وبشكل عام تختفي بعد بضعة أيام إلى بضعة أسابيع.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>بعض الآثار الجانبية يمكن أن تكون خطيرة وتحتاج إلى عناية طبية فورية. </strong></p><p dir="RTL"><strong>هذه الآثار الجانبية غير شائعة</strong> (قد تؤثر على ۱ من كل ۱۰۰ شخص) أو نادرة (قد تؤثر على ۱ في ۱,۰۰۰ شخص).</p><ul><li dir="RTL">إذا اصبت بطفح جلدي شديد، صعوبة بالتنفس , دوخة أو تورم بشكل ملحوظ في الوجه والحلق (علامات تحسس شديد).</li><li dir="RTL">إذا اصبت بمزيج من الطفح الجلدي الشديد، احمرار في الجلد ، تقرحات الشفتين، والعينين، أو الفم، تقشير الجلد، وارتفاع درجة الحرارة، وأعراض تشبه الإنفلونزا، وتضخم الغدد الليمفاوية (علامات رد فعل الحاد للجلد)</li><li dir="RTL">إذا لاحظت انخفاض في كمية إنتاج البول (علامة على وجود مشكلة في الكلى).</li><li dir="RTL">إذا اصبت بمزيج من خمول، وآلام أعلى البطن الأيمن، اصفرار أو زيادة اصفرار الجلد أو العينين والبول الداكن (علامات مشاكل في الكبد).</li><li dir="RTL">إذا واجهت صعوبة في التفكير، أو تذكر المعلومات، أو حل المشاكل، أو خمول مع انخفاض الطاقة الجسدية (علامات على ارتفاع مستوى الأمونيا في الدم، والتي قد تكون مرتبطة مع مشاكل الكبد أو الكلى وتؤدي إلى تغيير في وظيفة الدماغ).</li><li dir="RTL">إذا تتقيأ دم و / أو لديك براز أسود.</li><li dir="RTL">إذا واجهت ألم متكرر في البطن، و خاصة بعد تناول الطعام أو تناول المغنيسيوم.</li><li dir="RTL">إذا واجهت حرقة متكررة.</li><li dir="RTL">إذا كنت تعاني من فقدان جزئي للرؤية.</li><li dir="RTL">إذا كنت تعاني من ألم شديد في المعدة العليا (التهاب البنكرياس).</li></ul><p dir="RTL">توقف عن تناول هذا الدواء وأخبر طبيبك فوراً</p><p dir="RTL"><strong>بعض الآثار الجانبية يمكن أن تصبح خطيرة. </strong></p><p dir="RTL"><strong>هذه الآثار الجانبية غير شائعة. </strong></p><p dir="RTL">&bull; إذا واجهت مشاكل بالبصر مثل عدم وضوح الرؤية.</p><p dir="RTL">&bull; إذا واجهت مشاكل بالسمع مثل انخفاض السمع.</p><p dir="RTL">أخبر طبيبك في أقرب وقت ممكن.</p><p dir="RTL"><strong>الآثار الجانبية الأخرى .</strong></p><p dir="RTL"><strong>شائع جدا</strong> (قد يؤثر على أكثر من ۱ من كل &nbsp;۱۰أشخاص)</p><p dir="RTL">&bull; اضطراب في فحوصات وظائف الكلى.</p><p dir="RTL"><strong>شائع</strong> (قد يؤثر على شخص واحد من كل ۱۰ أشخاص)</p><p dir="RTL">&bull; اضطرابات الجهاز الهضمي، مثل الغثيان ،القيء ، الإسهال ألم في البطن ، &nbsp;الانتفاخ ، الإمساك وعسر الهضم</p><p dir="RTL">&bull; طفح جلدي</p><p dir="RTL">&bull; صداع رأسي</p><p dir="RTL">&bull; اضطراب في فحوصات وظائف الكبد</p><p dir="RTL">&bull; الحكة</p><p dir="RTL">&bull; اضطراب في فحص البول (البروتين في البول)</p><p dir="RTL">إذا كان أي من هذه يؤثر عليك بشدة، أخبر طبيبك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>غير شائع</strong> (قد يؤثر على شخص واحد من كل ۱۰۰ شخص)</p><p dir="RTL">&bull; الدوخة</p><p dir="RTL">&bull; الحمى</p><p dir="RTL">&bull; التهاب الحلق</p><p dir="RTL">&bull; تورم الذراعين أو الساقين</p><p dir="RTL">&bull; تغيير في لون الجلد</p><p dir="RTL">&bull; القلق</p><p dir="RTL">&bull; اضطراب النوم</p><p dir="RTL">&bull; التعب</p><p dir="RTL">إذا كان أي من هذه يؤثر عليك بشدة، أخبر طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية نادرة جدا</strong> (لا يمكن تقدير من البيانات المتاحة).</p><p dir="RTL">&bull; انخفاض عدد الخلايا المشاركة في تخثر الدم (الصفيحات)، انخفاض في عدد خلايا الدم الحمراء (تفاقم فقر الدم)، وانخفاض في عدد خلايا الدم البيضاء (العدلات) أو انخفاض في عدد جميع أنواع خلايا الدم.</p><p dir="RTL">&bull; تساقط الشعر</p><p dir="RTL">&bull; حصى الكلى</p><p dir="RTL">&bull; انخفاض كمية البول</p><p dir="RTL">&bull; جرح في المعدة أو جدار الأمعاء التي يمكن أن تكون مؤلمة وتسبب الغثيان</p><p dir="RTL">&bull; ألام شديدة في المعدة من الجهة العلوية (التهاب البنكرياس)</p><p dir="RTL">&bull; مستوى عالي من الحمض في الدم</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- يحفظ بعيداً عن متناول الأطفال.</p><p dir="RTL">- لا تستخدم <strong>فيرماتا</strong> بعد تاريخ انتهاء الصلاحية الذي هو مذكور على الشريط والكرتون.</p><p dir="RTL">- هذا الدواء لا يتطلب أي شروط تخزين خاصة، يخزن&nbsp; في درجة حرارة أقل من ٣۰ درجة مئوية.</p><p dir="RTL">- لا تستخدم أي عبوة تالفة أوأي عبوة تظهر عليها علامات العبث.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي ديفيراسيروكس.<br /><strong>فيرماتا<sup> </sup>۲٥۰ ملغم</strong> يحتوي على ۲٥۰ ملغم ديفيراسيروكس.<br /><strong>فيرماتا ٥۰۰ ملغم</strong> يحتوي على ٥۰۰ ملغم ديفيراسيروكس.<br />المكونات الأخرى هي: اللاكتوز، كروسبوفيدون، بوفيدون، كبريتات لوريل الصوديوم، سكرالوز، بيكربونات الصوديوم، حامض الستريك، ثاني أكسيد السيليكون الغروية، فيوماريت ستيريل الصوديوم.<br /><br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">الشكل الصيدلاني: أقراص قابلة للذوبان.<br />حجم عبوة <strong>فيرماتا ۲٥۰ ملغم:</strong> ٣۰ قرص قابل للذوبان<br />حجم عبوة <strong>فيرماتا ٥۰۰ ملغم:</strong> ٣۰ &nbsp;قرص قابل للذوبان</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الشركة الأردنية السويدية للمنتجات الطبية و التعقيم<br />ص.ب 851831 عمان 11185 الأردن<br />البريد الإلكتروني: &nbsp;info@joswe.com<br /><u>www.joswe.com</u><br />رقم الهاتف: ٦٥٧۲٨۳۲٧ ٩٦۲+، ٦٥٨٥٩٧٦٥ ٩٦۲+<br />رقم الفاكس: ٦٥٧۲٨۳۲٦ ٩٦۲+، ٦٥٨۱٤٥۲٦ ٩٦۲+</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>د- تمت مراجعة هذه النشرة في ۰٨</strong><strong>/ </strong><strong>۲۰۲۱</strong><strong>&nbsp;&nbsp;&nbsp; </strong><strong>؛ رقم المراجعة </strong><strong>R0</strong><strong>.</strong><br /><br /><strong>ه - للإبلاغ عن أي آثار جانبية:</strong></p><p dir="RTL"><strong>التواصل مع جوسوي:</strong></p><p dir="RTL">Saudipv@josweplant.com</p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي:</p><p dir="RTL">مركز الاتصال الموحد:19999</p><p dir="RTL">البريد الإلكتروني npc.drug@sfda.gov.sa:</p><p dir="RTL">الموقع الإلكتروني: &nbsp;&nbsp;https://ade.sfda. gov.sa</p></td></tr></tbody></table><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&nbsp;</p></td></tr></tbody></table><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;<p>الدواء مستحضر يؤثر على صحتك. واستهلاكه خلافاً للتعليمات يعرضك للخطر.</p><p>اتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها وتعليمات الصيدلي الذي صرفها لك.</p><p>الطبيب والصيدلي هما الخبيران في الدواء وفي نفعه وضرره.</p><p>لا تقطع مدة العلاج المحددة لك من تلقاء نفسك.</p><p>لا تكرر صرف الدواء بدون وصفة طبية.</p><p>لا تترك الأدوية في متناول أيدي الأطفال.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p style="text-indent:50px">مجلس وزراء الصحة العرب</p><p style="text-indent:50px">واتحاد الصيادلة العرب&nbsp;&nbsp;&nbsp;</p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت الموافقة على هذه النشرة آخر مرة في 08/2021؛ رقم المراجعة R0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Fermata® 250 mg Dispersible tablet 
Fermata® 500 mg Dispersible tablet
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Fermata® 250 mg Dispersible tablet Each Dispersible tablet contains 250 mg Deferasirox 
Fermata® 500 mg Dispersible tablet Each Dispersible tablet contains 500 mg Deferasirox 

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dispersible tablet 
Fermata® 250 mg Dispersible tablet: Round white to off-white tablets embossed with (JOSWE) from one side and bisected from the other side. 
Fermata® 500 mg Dispersible tablet: Round white to off-white tablets embossed with (- j) from one side and bisected from the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.1 Therapeutic indications<br />FERMATA&reg; (Deferasirox) is indicated for the treatment of chronic iron overload due to frequent blood transfusions (&ge;7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older.<br />FERMATA is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:<br />- in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (&ge;7 ml/kg/month of packed red blood cells) aged 2 to 5 years,<br />- in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (&lt;7 ml/kg/month of packed red blood cells) aged 2 years and older,<br />- in adult and paediatric patients with other anaemias aged 2 years and older.<br />FERMATA is also indicated for the treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with non-transfusion-dependent thalassaemia syndromes aged 10 years and older.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with FERMATA should be initiated and maintained by physicians experienced in the treatment of chronic iron overload<br />Posology<br />Transfusional iron overload<br />It is recommended that treatment be started after the transfusion of approximately 20 units (about 100 ml/kg) of packed red blood cells (PRBC) or when there is evidence from clinical monitoring that chronic iron overload is present (e.g. serum ferritin &gt;1,000 &mu;g/l). Doses (in mg/kg) must be calculated and rounded to the nearest whole tablet size.<br />The goals of iron chelation therapy are to remove the amount of iron administered in transfusions and, as required, to reduce the existing iron burden.<br />In case of switching from film-coated tablets/granules to dispersible tablets, the dose of dispersible tablets should be 40% higher than the dose of film-coated tablets/granules, rounded to the nearest whole tablet.<br />The corresponding doses for the different formulations are shown in the table below.</p><table border="1" cellspacing="1" cellpadding="1" style="width:871px"><caption>Table 1 Recommended doses for transfusional iron overload</caption><thead><tr><th scope="row" style="text-align:center; width:132px">&nbsp;</th><th scope="col" style="text-align:center; width:203px">Film-coated tablets/granules</th><th scope="col" style="text-align:center; width:180px">Dispersible tablets</th><th scope="col" style="text-align:center; width:226px">Transfusions</th><th scope="col" style="text-align:center; width:129px">Serum ferritin</th></tr></thead><tbody><tr><th scope="row" style="text-align:center; width:132px">Starting dose</th><td style="text-align:center; width:203px">14 mg/kg/day</td><td style="text-align:center; width:180px">20 mg/kg/day</td><td style="text-align:center; width:226px">After 20 units (about 100 ml/kg) of PRBC</td><td style="text-align:center; width:129px">&gt;1,000 &mu;g/l</td></tr><tr><th scope="row" rowspan="2" colspan="1" style="text-align:center; width:132px">Alternative<br />starting<br />doses</th><td style="text-align:center; width:203px">21 mg/kg/day</td><td style="text-align:center; width:180px">30 mg/kg/day</td><td style="text-align:center; width:226px">&gt;14 ml/kg/month of PRBC (approx. &gt;4 units/month for an adult)</td><td style="text-align:center; width:129px">&nbsp;</td></tr><tr><td style="text-align:center; width:203px">7 mg/kg/day</td><td style="text-align:center; width:180px">10 mg/kg/day</td><td style="text-align:center; width:226px">&lt;7 ml/kg/month of PRBC<br />(approx. &lt;2 units/month for<br />an adult)</td><td style="text-align:center; width:129px">&nbsp;</td></tr><tr><th scope="row" style="text-align:center; width:132px">For patients well<br />managed on<br />deferoxamine</th><td style="text-align:center; width:203px">One third of<br />deferoxamine<br />dose</td><td style="text-align:center; width:180px">Half of deferoxamine dose</td><td style="text-align:center; width:226px">&nbsp;</td><td style="text-align:center; width:129px">&nbsp;</td></tr><tr><th scope="row" style="text-align:center; width:132px">Monitoring</th><td style="text-align:center; width:203px">&nbsp;</td><td style="text-align:center; width:180px">&nbsp;</td><td style="text-align:center; width:226px">&nbsp;</td><td style="text-align:center; width:129px"><strong>Monthly</strong></td></tr><tr><th scope="row" style="text-align:center; width:132px">Target range</th><td style="text-align:center; width:203px">&nbsp;</td><td style="text-align:center; width:180px">&nbsp;</td><td style="text-align:center; width:226px">&nbsp;</td><td style="text-align:center; width:129px"><strong>500-1,000 &mu;g/l</strong></td></tr><tr><th scope="row" rowspan="3" colspan="1" style="text-align:center; width:132px">Adjustment steps<br />(every 3-6 months)</th><td rowspan="1" colspan="2" style="text-align:center; width:383px"><strong>Increase</strong></td><td style="text-align:center; width:226px">&nbsp;</td><td rowspan="2" colspan="1" style="text-align:center; width:129px">&gt;2,500 &mu;g/l</td></tr><tr><td style="text-align:center; width:203px">3.5 - 7 mg/kg/day<br />Up to 28 mg/kg/day</td><td style="text-align:center; width:180px">5-10<br />mg/kg/day<br />Up to 40 mg/kg/day</td><td style="text-align:center; width:226px">&nbsp;</td></tr><tr><td rowspan="1" colspan="2" style="text-align:center; width:383px">Decrease</td><td rowspan="1" colspan="2" style="text-align:center; width:355px">&nbsp;</td></tr><tr><th scope="row" style="text-align:center; width:132px">&nbsp;</th><td style="text-align:center; width:203px">3.5 - 7mg/kg/day<br />In patients treated with doses &gt;21 mg/kg/day</td><td style="text-align:center; width:180px">5-10 mg/kg/day<br />In patients treated with doses &gt;30 mg/kg/day</td><td style="text-align:center; width:226px">&nbsp;</td><td style="text-align:center; width:129px">&nbsp;</td></tr><tr><th scope="row" rowspan="1" colspan="3" style="text-align:center; width:515px">When target is reached&nbsp;</th><td rowspan="1" colspan="2" style="text-align:center; width:355px">500-1,000 &mu;g/l</td></tr><tr><th scope="row" style="text-align:center; width:132px">Maximum dose</th><td style="text-align:center; width:203px"><strong>28 mg/kg/day</strong></td><td style="text-align:center; width:180px">40 mg/kg/day</td><td style="text-align:center; width:226px">&nbsp;</td><td style="text-align:center; width:129px">&nbsp;</td></tr><tr><th scope="row" style="text-align:center; width:132px">Consider<br />interruption</th><td style="text-align:center; width:203px">&nbsp;</td><td style="text-align:center; width:180px">&nbsp;</td><td style="text-align:center; width:226px">&nbsp;</td><td style="text-align:center; width:129px"><strong>&lt;500 &mu;g/l</strong></td></tr></tbody></table><p>&nbsp;</p><p><em>Starting dose</em><br />The recommended initial daily dose of FERMATA dispersible tablets is 20 mg/kg body weight.<br />An initial daily dose of 30 mg/kg may be considered for patients who require reduction of elevated body iron levels and who are also receiving more than 14 ml/kg/month of packed red blood cells (approximately &gt;4 units/month for an adult).<br />An initial daily dose of 10 mg/kg may be considered for patients who do not require reduction of body iron levels and who are also receiving less than 7 ml/kg/month of packed red blood cells (approximately &lt;2 units/month for an adult). The patient&rsquo;s response must be monitored and a dose increase should be considered if sufficient efficacy is not obtained (see section 5.1).<br />For patients already well managed on treatment with deferoxamine, a starting dose of FERMATA dispersible tablets that is numerically half that of the deferoxamine dose could be considered (e.g. a patient receiving 40 mg/kg/day of deferoxamine for 5 days per week (or equivalent) could be transferred to a starting daily dose of 20 mg/kg/day of FERMATA dispersible tablets). When this results in a daily dose less than 20 mg/kg body weight, the patient&rsquo;s response must be monitored and a dose increase should be considered if sufficient efficacy is not obtained (see section 5.1).</p><p><br /><em>Dose adjustment</em><br />It is recommended that serum ferritin be monitored every month and that the dose of FERMATAbe adjusted, if necessary, every 3 to 6 months based on the trends in serum ferritin. Dose adjustments may be made in steps of 5 to 10 mg/kg and are to be tailored to the individual patient&rsquo;s response and therapeutic goals (maintenance or reduction of iron burden). In patients not adequately controlled with doses of 30 mg/kg (e.g. serum ferritin levels persistently above 2,500 &mu;g/l and not showing a decreasing trend over time), doses of up to 40 mg/kg may be considered. The availability of long-term efficacy and safety data with FERMATA dispersible tablets used at doses above 30 mg/kg is currently limited (264 patients followed for an average of 1 year after dose escalation). If only very poor haemosiderosis control is achieved at doses up to 30 mg/kg, a further increase (to a maximum of 40 mg/kg) may not achieve satisfactory control, and alternative treatment options may be considered. If no satisfactory control is achieved at doses above 30 mg/kg, treatment at such doses should not be maintained and alternative treatment options should be considered whenever possible. Doses above 40 mg/kg are not recommended because there is only limited experience with doses above this level.<br />In patients treated with doses greater than 30 mg/kg, dose reductions in steps of 5 to 10 mg/kg should be considered when control has been achieved (e.g. serum ferritin levels persistently below 2,500 &mu;g/l and showing a decreasing trend over time). In patients whose serum ferritin level has reached the target (usually between 500 and 1,000 &mu;g/l), dose reductions in steps of 5 to 10 mg/kg should be considered to maintain serum ferritin levels within the target range and to minimise the risk of overchelation. If serum ferritin falls consistently below 500 &mu;g/l, an interruption of treatment should be considered (see section 4.4)</p><p><br /><em>Non-transfusion-dependent thalassaemia syndromes</em><br />Chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration [LIC] &ge;5 mg Fe/g dry weight [dw] or serum ferritin consistently &gt;800 &mu;g/l). LIC is the preferred method of iron overload determination and should be used wherever available. Caution should be taken during chelation therapy to minimise the risk of overchelation in all patients (see section 4.4).</p><p>In case of switching from film-coated tablets/granules to dispersible tablets, the dose of dispersible tablets should be 40% higher than the dose of film-coated tablets/granules, rounded to the nearest whole tablet.</p><p>The corresponding doses for the different formulations are shown in the table below. Table 2 : Recommended doses for non-transfusion-dependent thalassaemia syndromes</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" align="center"><caption><strong>Table 2 : Recommended doses for non-transfusion-dependent thalassaemia syndromes</strong></caption><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Film-coated tablets/granules</strong></p></td><td style="vertical-align:top"><p><strong>D</strong><strong>i</strong><strong>spersible tablets</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>L</strong><strong>i</strong><strong>ver iron concentration (LIC)*</strong></p></td><td style="vertical-align:top"><p><strong>Serum ferritin</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Starting dose</strong></p></td><td style="vertical-align:top"><p><strong>7 mg/kg/day</strong></p></td><td style="vertical-align:top"><p><strong>10 mg/kg/day</strong></p></td><td style="vertical-align:top"><p>&ge;5 mg Fe/g dw</p></td><td colspan="2" style="vertical-align:top"><p>or</p></td><td style="vertical-align:top"><p>&gt;800 &mu;g/l</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Monitoring</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Monthly</strong></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>A</strong><strong>djustment</strong></p><p><strong>steps </strong>(every 3-6 months)</p></td><td colspan="2" style="vertical-align:top"><p><strong>Increase</strong></p></td><td colspan="4" style="vertical-align:top"><p>&ge;7 mg Fe/g dw&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;or&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&gt;2,000 &mu;g/l</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>3.5 - 7 mg/kg/day</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>5-10 mg/kg/day</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>D</strong><strong>ecrease</strong></p></td><td colspan="2" style="vertical-align:top"><p>&lt;7 mg Fe/g dw</p></td><td colspan="2" style="vertical-align:top"><p>&le;2,000 &mu;g/l</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>3.5 - 7 mg/kg/day</p></td><td style="vertical-align:top"><p>5-10</p><p>mg/kg/day</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Maximum dose</strong></p></td><td style="vertical-align:top"><p><strong>14 mg/kg/day</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>20 mg/kg/day</strong></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>7 mg/kg/day</strong></p></td><td style="vertical-align:top"><p><strong>10 mg/kg/day</strong></p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>For adults</p></td><td colspan="3" style="vertical-align:top"><p>not assessed&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;and</p></td><td style="vertical-align:top"><p>&le;2,000 &mu;g/l</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>For paediatric patients</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Interruption</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>&lt;</strong><strong>3 mg Fe/g dw&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;or</strong></p></td><td style="vertical-align:top"><p><strong>&lt;</strong><strong>300 &mu;g/l</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>R</strong><strong>etreatment</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>N</strong><strong>ot recommended</strong></p></td></tr></tbody></table><p>*LIC is the preferred method of iron overload determination.</p><p>&nbsp;</p><p><em>Starting dose</em></p><p>&nbsp;</p><p>The recommended initial daily dose of FERMATA dispersible tablets in patients with non- transfusion-dependent thalassaemia syndromes is 10 mg/kg body weight.</p><p>&nbsp;</p><p><em>D</em><em>ose adjustment</em></p><p>&nbsp;</p><p>It is recommended that serum ferritin be monitored every month to assess the patient&rsquo;s response to therapy and to minimise the risk of overchelation (see section 4.4). After every 3 to 6 months of treatment, a dose increase in increments of 5 to 10 mg/kg should be considered if the patient&rsquo;s LIC is</p><p>&ge;7 mg Fe/g dw, or if serum ferritin is consistently &gt;2,000 &mu;g/l and not showing a downward trend,</p><p>and the patient is tolerating the medicinal product well. Doses above 20 mg/kg are not recommended because there is no experience with doses above this level in patients with non-transfusion-dependent</p><p>thalassaemia syndromes.</p><p>&nbsp;</p><p>In patients in whom LIC was not assessed and serum ferritin is &le;2,000 &mu;g/l, dosing should not exceed</p><p>10 mg/kg.</p><p>&nbsp;</p><p>For patients in whom the dose was increased to &gt;10 mg/kg, dose reduction to 10 mg/kg or less is</p><p>recommended when LIC is &lt;7 mg Fe/g dw or serum ferritin is &le;2,000 &mu;g/l.</p><p><em>Treatment cessation</em></p><p>&nbsp;</p><p>Once a satisfactory body iron level has been achieved (LIC &lt;3 mg Fe/g dw or serum ferritin &lt;300 &mu;g/l), treatment should be stopped. There are no data available on the retreatment of patients who reaccumulate iron after having achieved a satisfactory body iron level and therefore retreatment cannot be recommended.</p><p>&nbsp;</p><p><em>Special populations</em></p><p>&nbsp;</p><p><em>Elderly patients (&ge;65 years of age)</em></p><p>The dosing recommendations for elderly patients are the same as described above. In clinical studies, elderly patients experienced a higher frequency of adverse reactions than younger patients (in particular, diarrhoea) and should be monitored closely for adverse reactions that may require a dose adjustment.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>&nbsp;</p><p>Transfusional iron overload:</p><p>The dosing recommendations for paediatric patients aged 2 to 17 years with transfusional iron overload are the same as for adult patients (see section 4.2). It is recommended that serum ferritin be monitored every month to assess the patient&rsquo;s response to therapy and to minimise the risk of overchelation (see section 4.4). Changes in weight of paediatric patients over time must be taken into account when calculating the dose.</p><p>&nbsp;</p><p>In children with transfusional iron overload aged between 2 and 5 years, exposure is lower than in adults (see section 5.2). This age group may therefore require higher doses than are necessary in adults. However, the initial dose should be the same as in adults, followed by individual titration.</p><p>&nbsp;</p><p>Non-transfusion-dependent thalassaemia syndromes:</p><p>In paediatric patients with non-transfusion-dependent thalassaemia syndromes, dosing should not exceed 10 mg/kg. In these patients, closer monitoring of LIC and serum ferritin is essential to avoid</p><p>overchelation (see section 4.4). In addition to monthly serum ferritin assessments, LIC should be</p><p>monitored every three months when serum ferritin is &le;800 &mu;g/l.</p><p>&nbsp;</p><p>Children from birth to 23 months:</p><p>The safety and efficacy of FERMATA in children from birth to 23 months of age have not been established. No data are available.</p><p>&nbsp;</p><p><em>Patients with renal impairment</em></p><p>FERMATA has not been studied in patients with renal impairment and is contraindicated in patients with estimated creatinine clearance &lt;60 ml/min (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p><em>Patients with hepatic impairment</em></p><p>&nbsp;</p><p>FERMATA is not recommended in patients with severe hepatic impairment (Child-Pugh Class C). In patients with moderate hepatic impairment (Child-Pugh Class B), the dose should be considerably reduced followed by progressive increase up to a limit of 50% (see sections 4.4 and 5.2), andmust be used with caution in such patients. Hepatic function in all patients should be monitored before treatment, every 2 weeks during the first month and then every month (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Method of administration</p><p>&nbsp;</p><p>For oral use.</p><p>FERMATA dispersible tablets must be taken once daily on an empty stomach at least 30 minutes before food, preferably at the same time each day (see sections 4.5 and 5.2).</p><p>&nbsp;</p><p>The dispersible tablets are dispersed by stirring in a glass of water or orange or apple juice (100 to 200 ml) until a fine suspension is obtained. After the suspension has been swallowed, any residue must be resuspended in a small volume of water or juice and swallowed. The tablets must not be chewed or swallowed whole (see also section 6.2).</p><p>&nbsp;</p><p><em>The score line is considered as a part of the tablet description and not to divide into equal doses</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Combination with other iron chelator therapies as the safety of such combinations has not been
established (see section 4.5).

Patients with estimated creatinine clearance <60 ml/min.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>R</u><u>enal function</u></p><p>&nbsp;</p><p>Deferasirox has been studied only in patients with baseline serum creatinine within the age- appropriate normal range.</p><p>&nbsp;</p><p>During clinical studies, increases in serum creatinine of &gt;33% on &ge;2 consecutive occasions, sometimes above the upper limit of the normal range, occurred in about 36% of patients. These were dose-dependent. About two-thirds of the patients showing serum creatinine increase returned below the 33% level without dose adjustment. In the remaining third the serum creatinine increase did not always respond to a dose reduction or a dose interruption. In some cases, only a stabilisation of the serum creatinine values has been observed after dose reduction. Cases of acute renal failure have been reported following post-marketing use of deferasirox (see section 4.8). In some post-marketing cases, renal function deterioration has led to renal failure requiring temporary or permanent dialysis.</p><p>&nbsp;</p><p>The causes of the rises in serum creatinine have not been elucidated. Particular attention should therefore be paid to monitoring of serum creatinine in patients who are concomitantly receiving medicinal products that depress renal function, and in patients who are receiving high doses of deferasirox and/or low rates of transfusion (&lt;7 ml/kg/month of packed red blood cells or &lt;2 units/month for an adult). While no increase in renal adverse events was observed after dose escalation of FERMATA dispersible tablets to doses above 30 mg/kg in clinical studies, an increased risk of renal adverse events with FERMATA dispersible tablet doses above 30 mg/kg cannot be excluded.</p><p>&nbsp;</p><p>It is recommended that serum creatinine be assessed in duplicate before initiating therapy. <strong>Serum creatinine, creatinine clearance </strong>(estimated with the Cockcroft-Gault or MDRD formula in adults and with the Schwartz formula in children) and/or plasma cystatin C levels <strong>should be monitored prior to therapy, weekly in the first month after initiation or modification of therapy with FERMATA (including switch of formulation), and monthly thereafter</strong>. Patients with pre-existing renal conditions and patients who are receiving medicinal products that depress renal function may be more at risk of complications. Care should be taken to maintain adequate hydration in patients who develop diarrhoea or vomiting.</p><p>There have been post-marketing reports of metabolic acidosis occurring during treatment with deferasirox. The majority of these patients had renal impairment, renal tubulopathy (Fanconi syndrome) or diarrhoea, or conditions where acid-base imbalance is a known complication. Acid-base balance should be monitored as clinically indicated in these populations. Interruption of FERMATA therapy should be considered in patients who develop metabolic acidosis.</p><p>Post-marketing cases of severe forms of renal tubulopathy (such as Fanconi syndrome) and renal failure associated with changes in consciousness in the context of hyperammonaemic encephalopathy have been reported in patients treated with deferasirox, mainly in children. It is recommended that hyperammonaemic encephalopathy be considered and ammonia levels measured in patients who develop unexplained changes in mental status while on FERMATA therapy.</p><p>&nbsp;</p><p><strong><u>T</u><u>able 3</u>&nbsp;Dose adjustment and interruption of treatment for renal monitoring</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Serum creatinine</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>C</strong><strong>r</strong><strong>eatinine clearance</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>B</strong><strong>e</strong><strong>f</strong><strong>ore initiation of therapy</strong></p></td><td style="vertical-align:top"><p>Twice (2x)</p></td><td style="vertical-align:top"><p>and</p></td><td style="vertical-align:top"><p>Once (1x)</p></td></tr><tr><td style="vertical-align:top"><p><strong>C</strong><strong>ontraindicated</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&lt;</strong><strong>60 ml/min</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Monitoring</strong></p><p>- First month after start of</p><p>therapy or dose modification (including switch of formulation)</p><p>- Thereafter</p></td><td style="vertical-align:top"><p>Weekly</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Monthly</p></td><td style="vertical-align:top"><p>And</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>and</p></td><td style="vertical-align:top"><p>Weekly</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Monthly</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>R</strong><strong>eduction of daily dose by 10 mg/kg/day </strong>(dispersible tablet formulation),</p><p><em>i</em><em>f following renal parameters are observed at <strong>t</strong><strong>wo </strong>consecutive visits and cannot be attributed to other causes</em></p></td></tr><tr><td style="vertical-align:top"><p>Adult patients</p></td><td style="vertical-align:top"><p>&gt;33% above pre-</p><p>treatment average</p></td><td style="vertical-align:top"><p>and</p></td><td style="vertical-align:top"><p>Decreases &lt;LLN*</p><p>(&lt;90 ml/min)</p></td></tr><tr><td style="vertical-align:top"><p>Paediatric patients</p></td><td style="vertical-align:top"><p>&gt; age appropriate</p><p>ULN**</p></td><td style="vertical-align:top"><p>and/or</p></td><td style="vertical-align:top"><p>Decreases &lt;LLN*</p><p>(&lt;90 ml/min)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>A</strong><strong>ft</strong><strong>er dose reduction, interrupt treatment, if</strong></p></td></tr><tr><td style="vertical-align:top"><p>Adult and paediatric</p></td><td style="vertical-align:top"><p>Remains &gt;33% above</p><p>pre-treatment average</p></td><td style="vertical-align:top"><p>and/or</p></td><td style="vertical-align:top"><p>Decreases &lt;LLN* (&lt;90</p><p>ml/min)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>*LLN: lower limit of the normal range</p><p>**ULN: upper limit of the normal range</p></td></tr></tbody></table><p>Treatment may be reinitiated depending on the individual clinical circumstances.</p><p>Dose reduction or interruption may be also considered if abnormalities occur in levels of markers of renal tubular function and/or as clinically indicated:</p><p>&bull; Proteinuria (test should be performed prior to therapy and monthly thereafter)</p><p>&bull; Glycosuria in non-diabetics and low levels of serum potassium, phosphate, magnesium or urate, phosphaturia, aminoaciduria (monitor as needed).</p><p>Renal tubulopathy has been mainly reported in children and adolescents with beta-thalassaemia treated with FERMATA.</p><p>Patients should be referred to a renal specialist, and further specialised investigations (such as renal biopsy) may be considered if the following occur despite dose reduction and interruption:</p><p>&bull; Serum creatinine remains significantly elevated and</p><p>&bull; Persistent abnormality in another marker of renal function (e.g. proteinuria, Fanconi Syndrome).</p><p>&nbsp;</p><p><u>H</u><u>epatic function</u></p><p>&nbsp;</p><p>Liver function test elevations have been observed in patients treated with deferasirox. Post-marketing cases of hepatic failure, some of which were fatal, have been reported. Severe forms associated with changes in consciousness in the context of hyperammonaemic encephalopathy, may occur in patients treated with deferasirox, particularly in children. It is recommended that hyperammonaemic encephalopathy be considered and ammonia levels measured in patients who develop unexplained changes in mental status while on FERMATAtherapy. Care should be taken to maintain adequate hydration in patients who experience volume-depleting events (such as diarrhoea or vomiting), particularly in children with acute illness. Most reports of hepatic failure involved patients with significant comorbidities including pre-existing chronic liver conditions (including cirrhosis and hepatitis C) and multi-organ failure. The role of deferasirox as a contributing or aggravating factor cannot be excluded (see section 4.8).</p><p>&nbsp;</p><p>It is recommended that serum transaminases, bilirubin and alkaline phosphatase be checked before the initiation of treatment, every 2 weeks during the first month and monthly thereafter. If there is a persistent and progressive increase in serum transaminase levels that cannot be attributed to other causes, FERMATA should be interrupted. Once the cause of the liver function test abnormalities has been clarified or after return to normal levels, cautious re-initiation of treatment at a lower dose followed by gradual dose escalation may be considered.</p><p>FERMATA is not recommended in patients with severe hepatic impairment (Child-Pugh Class C) (see section 5.2).</p><p>&nbsp;</p><p><strong>Table 4 Summary of safety monitoring recommendations</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>T</strong><strong>est</strong></p></td><td style="vertical-align:top"><p><strong>F</strong><strong>r</strong><strong>equency</strong></p></td></tr><tr><td style="vertical-align:top"><p>Serum creatinine</p></td><td style="vertical-align:top"><p>In duplicate prior to therapy.</p><p>Weekly during first month of therapy or after dose modification (including switch of formulation). Monthly thereafter.</p></td></tr><tr><td style="vertical-align:top"><p>Creatinine clearance and/or plasma cystatin C</p></td><td style="vertical-align:top"><p>Prior to therapy.</p><p>Weekly during first month of therapy or after dose modification (including switch of formulation).</p><p>Monthly thereafter.</p></td></tr><tr><td style="vertical-align:top"><p>Proteinuria</p></td><td style="vertical-align:top"><p>Prior to therapy.</p><p>Monthly thereafter.</p></td></tr><tr><td style="vertical-align:top"><p>Other markers of renal tubular function (such as</p><p>glycosuria in non-diabetics and low levels of serum potassium, phosphate, magnesium or</p><p>urate, phosphaturia, aminoaciduria)</p></td><td style="vertical-align:top"><p>As needed.</p></td></tr><tr><td style="vertical-align:top"><p>Serum transaminases, bilirubin, alkaline</p><p>phosphatase</p></td><td style="vertical-align:top"><p>Prior to therapy.</p><p>Every 2 weeks during first month of therapy. Monthly thereafter.</p></td></tr><tr><td style="vertical-align:top"><p>Auditory and ophthalmic testing</p></td><td style="vertical-align:top"><p>Prior to therapy.</p><p>Annually thereafter.</p></td></tr><tr><td style="vertical-align:top"><p>Body weight, height and sexual development</p></td><td style="vertical-align:top"><p>Prior to therapy.</p><p>Annually in paediatric patients.</p></td></tr></tbody></table><p>&nbsp;</p><p>In patients with a short life expectancy (e.g. high-risk myelodysplastic syndromes), especially when co-morbidities could increase the risk of adverse events, the benefit of FERMATA might be limited and may be inferior to risks. As a consequence, treatment with FERMATA is not recommended in these patients.</p><p>&nbsp;</p><p>Caution should be used in elderly patients due to a higher frequency of adverse reactions (in particular, diarrhoea).</p><p>&nbsp;</p><p>Data in children with non-transfusion-dependent thalassaemia are very limited (see section 5.1). As a consequence, FERMATA therapy should be closely monitored to detect adverse reactions and to follow iron burden in the paediatric population. In addition, before treating heavily iron-overloaded children with non-transfusion-dependent thalassaemia with FERMATA, the physician should be aware that the consequences of long-term exposure in such patients are currently not known.</p><p>&nbsp;</p><p><u>G</u><u>astrointestinal disorders</u></p><p>&nbsp;</p><p>Upper gastrointestinal ulceration and haemorrhage have been reported in patients, including children and adolescents, receiving deferasirox. Multiple ulcers have been observed in some patients (see section 4.8). There have been reports of ulcers complicated with digestive perforation. Also, there have been reports of fatal gastrointestinal haemorrhages, especially in elderly patients who had haematological malignancies and/or low platelet counts. Physicians and patients should remain alert for signs and symptoms of gastrointestinal ulceration and haemorrhage during FERMATA therapy. In case of gastrointestinal ulceration or haemorrhage, FERMATA should be discontinued and additional&nbsp;evaluation and treatment must be promptly initiated. Caution should be exercised in patients who are taking FERMATA in combination with substances that have known ulcerogenic potential, such as NSAIDs, corticosteroids, or oral bisphosphonates, in patients receiving anticoagulants and in patients with platelet counts below 50,000/mm3 (50 x 109/l) (see section 4.5).</p><p>&nbsp;</p><p><u>Skin disorders</u></p><p>&nbsp;</p><p>Skin rashes may appear during FERMATA treatment. The rashes resolve spontaneously in most cases. When interruption of treatment may be necessary, treatment may be reintroduced after resolution of the rash, at a lower dose followed by gradual dose escalation. In severe cases this reintroduction could be conducted in combination with a short period of oral steroid administration. Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS), which could be life-threatening or fatal, have been reported. If any SCAR is suspected, FERMATAshould be discontinued immediately and should not be reintroduced. At the time of prescription, patients should be advised of the signs and symptoms of severe skin reactions, and be closely monitored.</p><p>&nbsp;</p><p><u>H</u><u>y</u><u>persensitivity reactions</u></p><p>&nbsp;</p><p>Cases of serious hypersensitivity reactions (such as anaphylaxis and angioedema) have been reported in patients receiving deferasirox, with the onset of the reaction occurring in the majority of cases within the first month of treatment (see section 4.8). If such reactions occur, FERMATA should be discontinued and appropriate medical intervention instituted. Deferasirox should not be reintroduced</p><p>in patients who have experienced a hypersensitivity reaction due to the risk of anaphylactic shock (see section 4.3).</p><p>&nbsp;</p><p><u>V</u><u>i</u><u>sion and hearing</u></p><p>&nbsp;</p><p>Auditory (decreased hearing) and ocular (lens opacities) disturbances have been reported (see section 4.8). Auditory and ophthalmic testing (including fundoscopy) is recommended before the start of treatment and at regular intervals thereafter (every 12 months). If disturbances are noted during the treatment, dose reduction or interruption may be considered.</p><p>&nbsp;</p><p><u>B</u><u>l</u><u>ood disorders</u></p><p>There have been post-marketing reports of leukopenia, thrombocytopenia or pancytopenia (or aggravation of these cytopenias) and of aggravated anaemia in patients treated with deferasirox. Most of these patients had pre-existing haematological disorders that are frequently associated with bone marrow failure. However, a contributory or aggravating role cannot be excluded. Interruption of treatment should be considered in patients who develop unexplained cytopenia.</p><p>&nbsp;</p><p><u>O</u><u>t</u><u>her considerations</u></p><p>&nbsp;</p><p>Monthly monitoring of serum ferritin is recommended in order to assess the patient&rsquo;s response to therapy and to avoid overchelation (see section 4.2). Dose reduction or closer monitoring of renal and hepatic function, and serum ferritin levels are recommended during periods of treatment with high doses and when serum ferritin levels are close to the target range. If serum ferritin falls consistently below 500 &mu;g/l (in transfusional iron overload) or below 300 &mu;g/l (in non-transfusion-dependent thalassaemia syndromes), an interruption of treatment should be considered.</p><p>The results of the tests for serum creatinine, serum ferritin and serum transaminases should be recorded and regularly assessed for trends.</p><p>In two clinical studies, growth and sexual development of paediatric patients treated with deferasirox for up to 5 years were not affected (see section 4.8). However, as a general precautionary measure in the management of paediatric patients with transfusional iron overload, body weight, height and sexual development should be monitored prior to therapy and at regular intervals (every 12 months).</p><p>&nbsp;</p><p>Cardiac dysfunction is a known complication of severe iron overload. Cardiac function should be monitored in patients with severe iron overload during long-term treatment with FERMATA.</p><p>&nbsp;</p><p><u>Lactose content</u></p><p>&nbsp;</p><p>The dispersible tablets contain lactose.</p><p>Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The safety of deferasirox in combination with other iron chelators has not been established. Therefore, it must not be combined with other iron chelator therapies (see section 4.3).</p><p>&nbsp;</p><p><u>I</u><u>nteraction with food</u></p><p>&nbsp;</p><p>The bioavailability of deferasirox was increased to a variable extent when taken along with food. FERMATA dispersible tablets must therefore be taken on an empty stomach at least 30 minutes before food, preferably at the same time each day (see sections 4.2 and 5.2).</p><p>&nbsp;</p><p><u>A</u><u>g</u><u>ents that may decrease FERMATA systemic exposure</u></p><p>&nbsp;</p><p>Deferasirox metabolism depends on UGT enzymes. In a healthy volunteer study, the concomitant administration of deferasirox (single dose of 30 mg/kg, dispersible tablet formulation) and the potent UGT inducer, rifampicin, (repeated dose of 600 mg/day) resulted in a decrease of deferasirox exposure by 44% (90% CI: 37% - 51%). Therefore, the concomitant use of FERMATA with potent UGT inducers (e.g. rifampicin, carbamazepine, phenytoin, phenobarbital, ritonavir) may result in a</p><p>decrease in FERMATA efficacy. The patient&rsquo;s serum ferritin should be monitored during and after the combination, and the dose of FERMATA adjusted if necessary.</p><p>&nbsp;</p><p>Cholestyramine significantly reduced the deferasirox exposure in a mechanistic study to determine the degree of enterohepatic recycling (see section 5.2).</p><p>&nbsp;</p><p><u>I</u><u>nteraction with midazolam and other agents metabolised by CYP3A4</u></p><p>&nbsp;</p><p>In a healthy volunteer study, the concomitant administration of deferasirox dispersible tablets and midazolam (a CYP3A4 probe substrate) resulted in a decrease of midazolam exposure by 17% (90% CI: 8% - 26%). In the clinical setting, this effect may be more pronounced. Therefore, due to a possible decrease in efficacy, caution should be exercised when deferasirox is combined with substances metabolised through CYP3A4 (e.g. ciclosporin, simvastatin, hormonal contraceptive agents, bepridil, ergotamine).</p><p>&nbsp;</p><p><u>I</u><u>nteraction with repaglinide and other agents metabolised by CYP2C8</u></p><p>&nbsp;</p><p>In a healthy volunteer study, the concomitant administration of deferasirox as a moderate CYP2C8 inhibitor (30 mg/kg daily, dispersible tablet formulation), with repaglinide, a CYP2C8 substrate, given as a single dose of 0.5 mg, increased repaglinide AUC and Cmax about 2.3-fold (90% CI [2.03- 2.63]) and 1.6-fold (90% CI [1.42-1.84]), respectively. Since the interaction has not been established with dosages higher than 0.5 mg for repaglinide, the concomitant use of deferasirox with repaglinide should be avoided. If the combination appears necessary, careful clinical and blood glucose monitoring should be performed (see section 4.4). An interaction between deferasirox and other CYP2C8 substrates like paclitaxel cannot be excluded.</p><p>&nbsp;</p><p><u>I</u><u>nteraction with theophylline and other agents metabolised by CYP1A2</u></p><p>&nbsp;</p><p>In a healthy volunteer study, the concomitant administration of deferasirox as a CYP1A2 inhibitor (repeated dose of 30 mg/kg/day, dispersible tablet formulation) and the CYP1A2 substrate theophylline (single dose of 120 mg) resulted in an increase of theophylline AUC by 84% (90% CI: 73% to 95%). The single dose Cmax was not affected, but an increase of theophylline Cmax is expected to occur with chronic dosing. Therefore, the concomitant use of deferasirox with theophylline is not recommended. If deferasirox and theophylline are used concomitantly, monitoring of theophylline concentration and theophylline dose reduction should be considered. An interaction between deferasirox and other CYP1A2 substrates cannot be excluded. For substances that are predominantly metabolised by CYP1A2 and that have a narrow therapeutic index (e.g. clozapine, tizanidine), the same recommendations apply as for theophylline.</p><p>&nbsp;</p><p><u>O</u><u>t</u><u>her information</u></p><p>The concomitant administration of deferasirox and aluminium-containing antacid preparations has not been formally studied. Although deferasirox has a lower affinity for aluminium than for iron, it is not recommended to take deferasirox tablets with aluminium-containing antacid preparations.</p><p>The concomitant administration of deferasirox with substances that have known ulcerogenic potential, such as NSAIDs (including acetylsalicylic acid at high dosage), corticosteroids or oral bisphosphonates may increase the risk of gastrointestinal toxicity (see section 4.4). The concomitant administration of deferasirox with anticoagulants may also increase the risk of gastrointestinal haemorrhage. Close clinical monitoring is required when deferasirox is combined with these substances.</p><p>Concomitant administration of deferasirox and busulfan resulted in an increase of busulfan exposure (AUC), but the mechanism of the interaction remains unclear. If possible, evaluation of the pharmacokinetics (AUC, clearance) of a busulfan test dose should be performed to allow dose adjustment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>No clinical data on exposed pregnancies are available for deferasirox. Studies in animals have shown some reproductive toxicity at maternally toxic doses (see section 5.3). The potential risk for humans is unknown.</p><p>As a precaution, it is recommended that FERMATA is not used during pregnancy unless clearly necessary.</p><p>FERMATA may decrease the efficacy of hormonal contraceptives (see section 4.5). Women of childbearing potential are recommended to use additional or alternative non-hormonal methods of contraception when using FERMATA.</p><p><u>B</u><u>r</u><u>east-feeding</u></p><p>In animal studies, deferasirox was found to be rapidly and extensively secreted into maternal milk. No effect on the offspring was noted. It is not known if deferasirox is secreted into human milk. Breast- feeding while taking FERMATA is not recommended.</p><p><u>Fertility</u></p><p>No fertility data is available for humans. In animals, no adverse effects on male or female fertility were found (see section 5.3)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>FERMATA has minor influence on the ability to drive and use machines. Patients experiencing the uncommon adverse reaction of dizziness should exercise caution when driving or operating machines (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The most frequent reactions reported during chronic treatment with deferasirox dispersible tablets in adult and paediatric patients include gastrointestinal disturbances (mainly nausea, vomiting, diarrhoea or abdominal pain) and skin rash. Diarrhoea is reported more commonly in paediatric patients aged 2 to 5 years and in the elderly. These reactions are dose-dependent, mostly mild to moderate, generally transient and mostly resolve even if treatment is continued.</p><p>During clinical studies, dose-dependent increases in serum creatinine occurred in about 36% of patients, though most remained within the normal range. Decreases in mean creatinine clearance have been observed in both paediatric and adult patients with beta-thalassemia and iron overload during the first year of treatment, but there is evidence that this does not decrease further in subsequent years of treatment. Elevations of liver transaminases have been reported. Safety monitoring schedules for renal and liver parameters are recommended. Auditory (decreased hearing) and ocular (lens opacities) disturbances are uncommon, and yearly examinations are also recommended (see section 4.4).</p><p>Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported with the use of FERMATA (see section 4.4).</p><p><u>T</u><u>abulated list of adverse reactions</u></p><p>Adverse reactions are ranked below using the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p><strong>Table 5:</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>B</strong><strong>l</strong><strong>ood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Pancytopenia1, thrombocytopenia1, anaemia</p><p>aggravated1, neutropenia1</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions (including</p><p>anaphylactic reactions and angioedema)1</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Metabolic acidosis1</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>P</strong><strong>sychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Anxiety, sleep disorder</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>N</strong><strong>ervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Dizziness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>E</strong><strong>ye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Cataract, maculopathy</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Optic neuritis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>E</strong><strong>ar and labyrinth disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Deafness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>R</strong><strong>espiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Laryngeal pain</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>G</strong><strong>astrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Diarrhoea, constipation, vomiting, nausea,</p><p>abdominal pain, abdominal distension, dyspepsia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Gastrointestinal haemorrhage, gastric ulcer</p><p>(including multiple ulcers), duodenal ulcer, gastritis</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Oesophagitis</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Gastrointestinal perforation1, acute</p><p>pancreatitis1</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>H</strong><strong>epatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Transaminases increased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Hepatitis, cholelithiasis</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Hepatic failure1, 2</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Rash, pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Pigmentation disorder</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Drug reaction with eosinophilia and systemic</p><p>symptoms (DRESS)</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Stevens-Johnson syndrome1, hypersensitivity</p><p>vasculitis1, urticaria1, erythema multiforme1, alopecia1, toxic epidermal necrolysis (TEN)1</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>R</strong><strong>enal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Blood creatinine increased</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Proteinuria</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Renal tubular disorder2 (acquired Fanconi</p><p>syndrome), glycosuria</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Acute renal failure1, 2, tubulointerstitial</p><p>nephritis1, nephrolithiasis1, renal tubular necrosis1</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>G</strong><strong>eneral disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Pyrexia, oedema, fatigue</p></td></tr></tbody></table><p>1 Adverse reactions reported during post-marketing experience. These are derived from spontaneous reports for which it is not always possible to reliably establish frequency or a causal relationship to exposure to the medicinal product.</p><p>2 Severe forms associated with changes in consciousness in the context of hyperammonaemic encephalopathy have been reported</p><p><u>D</u><u>escription of selected adverse reactions</u></p><p>&nbsp;</p><p>Gallstones and related biliary disorders were reported in about 2% of patients. Elevations of liver transaminases were reported as an adverse reaction in 2% of patients. Elevations of transaminases greater than 10 times the upper limit of the normal range, suggestive of hepatitis, were uncommon (0.3%). During post-marketing experience, hepatic failure, sometimes fatal, has been reported with deferasirox (see section 4.4). There have been post-marketing reports of metabolic acidosis. The majority of these patients had renal impairment, renal tubulopathy (Fanconi syndrome) or diarrhoea, or conditions where acid-base imbalance is a known complication (see section 4.4). Cases of serious acute pancreatitis were observed without documented underlying biliary conditions. As with other iron chelator treatment, high-frequency hearing loss and lenticular opacities (early cataracts) have been uncommonly observed in patients treated with deferasirox (see section 4.4).</p><p>&nbsp;</p><p><u>C</u><u>r</u><u>eatinine clearance in transfusional iron overload</u></p><p>&nbsp;</p><p>In a retrospective meta-analysis of 2,102 adult and paediatric beta-thalassaemia patients with transfusional iron overload treated with deferasirox dispersible tablets in two randomised and four open label studies of up to five years&rsquo; duration, a mean creatinine clearance decrease of 13.2% in adult patients (95% CI: -14.4% to -12.1%; n=935) and 9.9% (95% CI: -11.1% to -8.6%; n=1,142) in</p><p>paediatric patients was observed during the first year of treatment. In 250 patients who were followed for up to five years, no further decrease in mean creatinine clearance levels was observed.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>C</u><u>li</u><u>n</u><u>i</u><u>cal study in patients with non-transfusion-dependent thalassaemia syndromes</u></p><p>&nbsp;</p><p>In a 1-year study in patients with non-transfusion-dependent thalassaemia syndromes and iron overload (dispersible tablets at a dose of 10 mg/kg/day), diarrhoea (9.1%), rash (9.1%), and nausea (7.3%) were the most frequent study drug-related adverse events. Abnormal serum creatinine and creatinine clearance values were reported in 5.5% and 1.8% of patients, respectively. Elevations of liver transaminases greater than 2 times the baseline and 5 times the upper limit of normal were reported in 1.8% of patients.</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>&nbsp;</p><p>In two clinical studies, growth and sexual development of paediatric patients treated with deferasirox for up to 5 years were not affected (see section 4.4).</p><p>Diarrhoea is reported more commonly in paediatric patients aged 2 to 5 years than in older patients. Renal tubulopathy has been mainly reported in children and adolescents with beta-thalassaemia</p><p>treated with deferasirox. In post-marketing reports, a high proportion of cases of metabolic acidosis</p><p>occurred in children in the context of Fanconi syndrome.</p><p>&nbsp;</p><p>Acute pancreatitis has been reported, particularly in children and adolescents.</p><p>&nbsp;</p><p><u>T</u><u>o reports any side effect (s):</u> Contact JOSWE Medical:</p><p>Saudipv@josweplant.com</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center :19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https ://ade.sfda.gov.sa</p></td></tr></tbody></table><p>Early signs of acute overdose are digestive effects such as abdominal pain, diarrhoea, nausea and vomiting. Hepatic and renal disorders have been reported, including cases of liver enzyme and creatinine increased with recovery after treatment discontinuation. An erroneously administered single dose of 90 mg/kg led to Fanconi syndrome which resolved after treatment.</p><p>&nbsp;</p><p>There is no specific antidote for deferasirox. Standard procedures for management of overdose may be indicated as well as symptomatic treatment, as medically appropriate.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Early signs of acute overdose are digestive effects such as abdominal pain, diarrhoea, nausea and vomiting. Hepatic and renal disorders have been reported, including cases of liver enzyme and creatinine increased with recovery after treatment discontinuation. An erroneously administered single dose of 90 mg/kg led to Fanconi syndrome which resolved after treatment.</p><p>There is no specific antidote for deferasirox. Standard procedures for management of overdose may be indicated as well as symptomatic treatment, as medically appropriate.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Iron chelating agents, ATC code: V03AC03</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Deferasirox is an orally active chelator that is highly selective for iron (III). It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. Deferasirox promotes excretion of iron, primarily in the faeces. Deferasirox has low affinity for zinc and copper, and does not cause constant low serum levels of these metals.</p><p><u>Pharmacodynamic effects</u></p><p>In an iron-balance metabolic study in iron-overloaded adult thalassaemic patients, deferasirox at daily doses of 10, 20 and 40 mg/kg (dispersible tablet formulation) induced the mean net excretion of 0.119, 0.329 and 0.445 mg Fe/kg body weight/day, respectively.</p><p><u>C</u><u>li</u><u>n</u><u>i</u><u>cal efficacy and safety</u></p><p>Clinical efficacy studies were conducted with deferasirox dispersible tablets.</p><p>Defirasirox has been investogated in 411 adult (aged &gt;16 years) and 292 peadiatric patients (aged 2 &lt;16 years) with chronic iron overload due to blood transfusions. Of the paediatric patients 52 were aged 2 to 5 years. The underlying conditions requiring transfusion included beta-thalassaemia, sickle cell disease and other congenital and acquired anaemias (myelodysplastic syndromes [MDS], Diamond-Blackfan syndrome, aplastic anaemia and other very rare anaemias).</p><p>Daily treatment with the deferasirox dispersible tablet formulation at doses of 20 and 30 mg/kg for one year in frequently transfused adult and paediatric patients with beta-thalassaemia led to reductions in indicators of total body iron; liver iron concentration was reduced by about -0.4 and -8.9 mg Fe/g liver (biopsy dry weight (dw)) on average, respectively, and serum ferritin was reduced by about -36 and -926 &mu;g/l on average, respectively. At these same doses the ratios of iron excretion: iron intake were 1.02 (indicating net iron balance) and 1.67 (indicating net iron removal), respectively. Deferasirox induced similar responses in iron-overloaded patients with other anaemias. Daily doses of 10 mg/kg (dispersible tablet formulation) for one year could maintain liver iron and serum ferritin levels and induce net iron balance in patients receiving infrequent transfusions or exchange transfusions. Serum ferritin assessed by monthly monitoring reflected changes in liver iron concentration indicating that trends in serum ferritin can be used to monitor response to therapy. Limited clinical data (29 patients with normal cardiac function at baseline) using MRI indicate that treatment with deferasirox 10-30 mg/kg/day (dispersible tablet formulation) for 1 year may also reduce levels of iron in the heart (on average, MRI T2* increased from 18.3 to 23.0 milliseconds).</p><p>The principal analysis of the pivotal comparative study in 586 patients suffering from beta- thalassaemia and transfusional iron overload did not demonstrate non-inferiority of deferasirox dispersible tablets to deferoxamine in the analysis of the total patient population. It appeared from a post-hoc analysis of this study that, in the subgroup of patients with liver iron concentration &ge;7 mg Fe/g dw treated with deferasirox dispersible tablets (20 and 30 mg/kg) or deferoxamine (35 to &ge;50 mg/kg), the non-inferiority criteria were achieved. However, in patients with liver iron concentration &lt;7 mg Fe/g dw treated with deferasirox dispersible tablets (5 and 10 mg/kg) or deferoxamine (20 to 35 mg/kg), non-inferiority was not established due to imbalance in the dosing of the two chelators. This imbalance occurred because patients on deferoxamine were allowed to remain on their pre-study dose even if it was higher than the protocol specified dose. Fifty-six patients under the age of 6 years participated in this pivotal study, 28 of them receiving deferasirox dispersible tablets.</p><p>It appeared from preclinical and clinical studies that deferasirox dispersible tablets could be as active as deferoxamine when used in a dose ratio of 2:1 (i.e. a dose of deferasirox dispersible tablets that is numerically half of the deferoxamine dose). However, this dosing recommendation was not prospectively assessed in the clinical studies.</p><p>In addition, in patients with liver iron concentration &ge;7 mg Fe/g dw with various rare anaemias or sickle cell disease, deferasirox dispersible tablets up to 20 and 30 mg/kg produced a decrease in liver iron concentration and serum ferritin comparable to that obtained in patients with beta-thalassaemia.</p><p>A placebo-controlled randomised study was performed in 225 patients with MDS (Low/Int-1 risk) and transfusional iron overload. The results of this study suggest that there is a positive impact of deferasirox on event-free survival (EFS, a composite endpoint including non-fatal cardiac or liver events) and serum ferritin levels. The safety profile was consistent with previous studies in adult MDS patients.</p><p>In a 5-year observational study in which 267 children aged 2 to &lt;6 years (at enrollment) with transfusional haemosiderosis received deferasirox, there were no clinically meaningful differences in the safety and tolerability profile of Exjade in paediatric patients aged 2 to &lt;6 years compared to the overall adult and older paediatric population, including increases in serum creatinine of &gt;33% and above the upper limit of normal on &ge;2 consecutive occasions (3.1%), and elevation of alanine aminotransferase (ALT) greater than 5 times the upper limit of normal (4.3%). Single events of increase in ALT and aspartate aminotransferase were reported in 20.0% and 8.3%, respectively, of the 145 patients who completed the study.</p><p>In a study to assess the safety of deferasirox film-coated and dispersible tablets, 173 adult and paediatric patients with transfusion dependent thalassaemia or myelodysplastic syndrome were treated for 24 weeks. A comparable safety profile for film-coated and dispersible tablets was observed.</p><p>In patients with non-transfusion-dependent thalassaemia syndromes and iron overload, treatment with deferasirox dispersible tablets was assessed in a 1-year, randomised, double-blind, placebo-controlled study. The study compared the efficacy of two different deferasirox dispersible tablet regimens (starting doses of 5 and 10 mg/kg/day, 55 patients in each arm) and of matching placebo (56 patients). The study enrolled 145 adult and 21 paediatric patients. The primary efficacy parameter was the change in liver iron concentration (LIC) from baseline after 12 months of treatment. One of the secondary efficacy parameters was the change in serum ferritin between baseline and fourth quarter. At a starting dose of 10 mg/kg/day, deferasirox dispersible tablets led to reductions in indicators of total body iron. On average, liver iron concentration decreased by 3.80 mg Fe/g dw in patients treated with deferasirox dispersible tablets (starting dose 10 mg/kg/day) and increased by 0.38 mg Fe/g dw in patients treated with placebo (p&lt;0.001). On average, serum ferritin decreased by 222.0 &mu;g/l in patients treated with deferasirox dispersible tablets (starting dose 10 mg/kg/day) and increased by 115 &mu;g/l in patients treated with placebo (p&lt;0.001).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>A</u><u>bsorption</u></p><p>Deferasirox (dispersible tablet formulation) is absorbed following oral administration with a median time to maximum plasma concentration (tmax) of about 1.5 to 4 hours. The absolute bioavailability (AUC) of deferasirox (dispersible tablet formulation) is about 70% compared to an intravenous dose.</p><p>Total exposure (AUC) was approximately doubled when taken along with a high-fat breakfast (fat content &gt;50% of calories) and by about 50% when taken along with a standard breakfast. The bioavailability (AUC) of deferasirox was moderately (approx. 13&ndash;25%) elevated when taken 30 minutes before meals with normal or high fat content.</p><p><u>Di</u><u>stribution</u></p><p>Deferasirox is highly (99%) protein bound to plasma proteins, almost exclusively serum albumin, and has a small volume of distribution of approximately 14 litres in adults.</p><p>B<u>i</u><u>otransformation</u></p><p>Glucuronidation is the main metabolic pathway for deferasirox, with subsequent biliary excretion. Deconjugation of glucuronidates in the intestine and subsequent reabsorption (enterohepatic recycling) is likely to occur: in a healthy volunteer study, the administration of cholestyramine after a single dose of deferasirox resulted in a 45% decrease in deferasirox exposure (AUC).</p><p>Deferasirox is mainly glucuronidated by UGT1A1 and to a lesser extent UGT1A3. CYP450-catalysed (oxidative) metabolism of deferasirox appears to be minor in humans (about 8%). No inhibition of deferasirox metabolism by hydroxyurea was observed <em>in vitro</em>.</p><p><u>Elimination</u></p><p>Deferasirox and its metabolites are primarily excreted in the faeces (84% of the dose). Renal excretion of deferasirox and its metabolites is minimal (8% of the dose). The mean elimination half-life (t1/2) ranged from 8 to 16 hours. The transporters MRP2 and MXR (BCRP) are involved in the biliary excretion of deferasirox.</p><p><u>Linearity / non-linearity</u></p><p>The Cmax and AUC0-24h of deferasirox increase approximately linearly with dose under steady-state conditions. Upon multiple dosing exposure increased by an accumulation factor of 1.3 to 2.3.</p><p><u>C</u><u>haracteristics in patients</u></p><p><em>Paediatric patients</em></p><p>The overall exposure of adolescents (12 to &le;17 years) and children (2 to &lt;12 years) to deferasirox</p><p>after single and multiple doses was lower than that in adult patients. In children younger than 6 years old exposure was about 50% lower than in adults. Since dosing is individually adjusted according to</p><p>response this is not expected to have clinical consequences.</p><p><em>G</em><em>ender</em></p><p>Females have a moderately lower apparent clearance (by 17.5%) for deferasirox compared to males. Since dosing is individually adjusted according to response this is not expected to have clinical</p><p>consequences.</p><p><em>Elderly patients</em></p><p>The pharmacokinetics of deferasirox have not been studied in elderly patients (aged 65 or older).</p><p><em>Renal or hepatic impairment</em></p><p>The pharmacokinetics of deferasirox have not been studied in patients with renal impairment. The pharmacokinetics of deferasirox were not influenced by liver transaminase levels up to 5 times the upper limit of the normal range.</p><p>In a clinical study using single doses of 20 mg/kg deferasirox dispersible tablets, the average exposure was increased by 16% in subjects with mild hepatic impairment (Child-Pugh Class A) and by 76% in subjects with moderate hepatic impairment (Child-Pugh Class B) compared to subjects with normal hepatic function. The average Cmax of deferasirox in subjects with mild or moderate hepatic</p><p>impairment was increased by 22%. Exposure was increased 2.8-fold in one subject with severe hepatic impairment (Child-Pugh Class C) (see sections 4.2 and 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity or carcinogenic potential. The main findings were kidney toxicity and lens opacity (cataracts). Similar findings were observed in neonatal and juvenile animals. The kidney toxicity is considered mainly due to iron deprivation in animals that were not previously overloaded with iron.</p><p>Tests of genotoxicity <em>in vitro </em>were negative (Ames test, chromosomal aberration test) while deferasirox caused formation of micronuclei <em>in vivo </em>in the bone marrow, but not liver, of non-iron- loaded rats at lethal doses. No such effects were observed in iron-preloaded rats. Deferasirox was not carcinogenic when administered to rats in a 2-year study and transgenic p53+/- heterozygous mice in a 6-month study.</p><p>The potential for toxicity to reproduction was assessed in rats and rabbits. Deferasirox was not teratogenic, but caused increased frequency of skeletal variations and stillborn pups in rats at high doses that were severely toxic to the non-iron-overloaded mother. Deferasirox did not cause other effects on fertility or reproduction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.1 List of excipients</strong></p><ul><li>Povidone</li><li>Sodium Lauryl sulphate</li><li>Crospovidone Lactose Sucralose</li><li>Sodium bicarbonate</li><li>Citric acid</li><li>Colloidal silicone dioxide</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dispersion in carbonated drinks or milk is not recommended due to foaming and slow dispersion, respectively</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminum /Aluminum blisters. Fermata 250 mg Dispersible Tablet:</p><p>Packs containing 30 dispersible tablets.</p><p>Fermata 500 mg Dispersible Tablet: Pack containing 30 dispersible tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jordan Sweden Medical and Sterilization Company (JOSWE-medical) P.O. Box 851831 Amman 11185 Jordan
E-mail: info@joswe.com
Head office: Sweifyeh.
Tel: +962 6 5859765 - + 962 6 5812748
Fax: +962 6 5814526
Fax: +962 6 5728326
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                08/2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>